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The PhD started as a project derived from the Bergen fMRI Group with the title: 
“Cognitive and neuronal correlates of Autism Spectrum Disorder: Structural and 
functional MR imaging”. The aim of this project was to study structural and 
functional changes associated with autism spectrum disorder (ASD) using 
multimodal magnetic resonance imaging (MRI). 
After some time, I came to the understanding that the magnetic resonance 
spectroscopy (MRS) technique was not as straight forward as I expected it to be. This 
counted in particular for the more advanced g-aminobutyric acid (GABA) edited 
MEscher-GArwood Point RESolved Spectroscopy (MEGA-PRESS) sequence – 
which had an important part in the ASD project. MEGA-PRESS with all its pitfalls 
and possibilities, intrigued me, and my focus started slowly shifting from a 
MRI/neuropsychiatric view to a more MRS/methodical view. I found that more 
reproducibility studies on basic MRS parameters in MEGA-PRESS were needed. The 
GABA edited MEGA-PRESS reproducibility study is a result of this. In addition, the 
increased interest in GABA edited MEGA-PRESS in our group led to a collaboration 
with other research cites worldwide.  
After the work on GABA edited MEGA-PRESS, expanding the focus to glutathione 
edited MEGA-PRESS was the natural next step to pursue.  
The continuation of the work in this thesis would be to bring back the optimized 
MRS sequences to the neurologists, the psychiatrists/psychologists and the 
neuroscientists for them to explore important research questions regarding disease 
and health. My contribution is a better way of interpreting the MRS results and 
communicating whether the results are reliable or not.  
A few comments:  
• When MRS is described, it refers to 1H brain MRS at a 3.0 T scanner if 
nothing else is mentioned.  
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• Glutathione exists in two forms, reduced (GSH) and oxidized (GSSG). When 
glutathione is mentioned in this work, it refers to reduced glutathione, in line 
with common practice in the literature. 
• Most of the GSH measurements and the initial analysis in the third study of 
this thesis were performed during the last two weeks before Christmas 2016, 
hence the name: The “Christmas phantom” study.  
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Scientific environment  
The project is derived from Bergen fMRI Group in cooperation with the Radiology 
Department at Haukeland University Hospital. The Bergen fMRI Group is an 
interdisciplinary research group at the University of Bergen and Haukeland 
University Hospital with interests in fMRI, MRS and related MR methods. A MRS 
interest group within the Bergen fMRI Group have been particularly involved in this 
project, with the joint leaders of the fMRI group Karsten Specth and Renate Grüner, 
Lars Ersland, Alex R Craven, Gerhard Dwyer, Cecilie Rygh, Marco Hirnstein, 
Kristiina Kampus and Kenneth Hugdahl as the most frequent participants. 
International collaborators are Ralph Noeske, Senior Scientist in GE and Felix 
Raschke at the University of Nottingham, Division of Radiological and Imaging 
Science. Mark Mikkelsen and Georg Oeltzschner at the Johns Hopkins Medicine 
Department of Radiology and Radiological Science in Baltimore. 
My main supervisor is Mona K Beyer, neuroradiologist at the Department of 
Radiology and Nuclear Medicine, Oslo University Hospital. Co-supervisors are 
Physicist Lars Ersland at the Department of Clinical Engineering, Haukeland 
University Hospital and professor Kenneth Hugdahl, former leader of the Bergen 
fMRI group.  
Researchers involved to the ASD part of the project are: Child psychiatrists Maj Britt 
Posserud and head of Department of Clinical Psychology Åsa Hammar. They have 
been professional advisers on ASD, reviewing the documentation of the clinical 
assessment leading to an ASD diagnosis and supervising the clinical interviews. 
Professor Emeritus in medical microbial ecology Tore Midtvedt and leader of the 
BioMed Clinics Research Lab Hanne B Walker, have been deeply involved in the 
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Proton MR spectroscopy (MRS) is a well-established method for measuring the 
relative concentration of a wide range of metabolites in the human brain 
noninvasively. Lately, more advanced spectroscopic techniques, such as MEGA-
PRESS, have emerged enabling us to measure low concentrated metabolites with 
complex peak splitting patterns. Examples of such metabolites are the main inhibitory 
brain neurotransmitter, g-aminobutyric acid (GABA), and the main brain antioxidant, 
glutathione (GSH). Impairment of both GABA and GSH have been implicated in the 
pathophysiology of several psychiatric and neurodegenerative disorders, including 
schizophrenia, bipolar disorder, autism spectrum disorder (ASD), multiple sclerosis, 
Alzheimer’s disease, amyotrophic lateral sclerosis and Parkinson disease. An 
accurate and reliable quantification of these metabolites in vivo is therefore of utmost 
interest and clinical relevance.  
The PhD started with an ASD focus, setting out to examine brain MRS measurable 
differences between boys with ASD and controls. The focus, however, soon shifted to 
the methodological aspect of MRS, with a desire to contribute in establishing reliable 
MRS techniques for measuring GABA and GSH in the human brain. 
Aims: 
1.) The aim of the ASD study was to explore the excitatory/inhibitory hypothesis 
in children with ASD by looking for imbalances in brain metabolites in boys 
with ASD compared with typically developing controls with standard and 
advanced MRS techniques.   
2.) Validating GABA and GSH edited MEGA-PRESS, and comparing these 
sequences to the standard single voxel measurements; short TE STEAM and 




Four different studies were performed, all on a 3.0 T GE MRI scanner. 
1. The ASD study: 14 boys with ASD and 24 age-matched controls were 
examined with both the GABA edited MEGA-PRESS and PRESS sequence. 
Autism symptom severity were reported by the Autism Spectrum Screening 
Questionnaire (ASSQ). 
2. The GABA reprod study: Two 20 min long GABA edited MEGA-PRESS 
acquisition were performed in 21 healthy young male volunteers. The 
participants were scanned twice with identical protocols. By applying a time-
windowing approach, within-and between-session reproducibility was 
calculated.  
3. The “Christmas phantom” study: 122 GSH edited MEGA-PRESS and PRESS 
spectra of a phantom containing GSH were acquired over a time period of 11 
days. The resulting decaying GSH curve (GSH oxidizes to GSSG) were 
modelled.  A 1-year-after follow-up acquisition for both sequences was also 
performed. 
4. The GSH reprod study: GSH edited MEGA-PRESS and short TE STEAM and 
PRESS acquisitions were performed in 36 healthy volunteers. The participants 
were scanned twice with identical protocols, one week apart. The time-
windowing approach was applied for within- and between-session 
reproducibility for GSH edited MEGA-PRESS. Differences between 
quantified GSH levels between males and females were examined, and the 
three different methods of measuring GSH were evaluated. 
Main Results: 
1. There was a significant negative correlation in the ASD group between ASSQ and 
GABA levels, however there was no significant difference between the ASD group 
and the control group in MEGA-PRESS measured GABA levels. 
2. Increasing the number of repetitions in GABA edited MEGA-PRESS showed 
improvements for within- and between-session reproducibility up to about 218 paired 
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repetitions (scan length ~ 13 min). Gannet combined with LCModel proved the best 
method processing the GABA data.  
3. Both GSH edited MEGA-PRESS and PRESS were able to measure the degradation 
of GSH in the phantom, however the modelled GSH edited MEGA-PRESS 
degradation curve was more accurate than PRESS.  
4. Between-session variability of GSH edited MEGA-PRESS stabilised at around 128 
paired repetitions (~8 min). There were no significant correlations between GSH 
measured with MEGA-PRESS, STEAM and PRESS, and no differences in measured 
GSH levels between males and females.  
Conclusion: 
In line with other studies, the ASD participants have GABA values that seem to 
change with their clinical severity although there was no group difference with 
healthy controls. For both GABA and GSH, it is possible to acquire reproducible 
MEGA-PRESS measurements. GSH edited MEGA-PRESS measurements have 
somewhat higher coefficient of variation (meaning lower reproducibility), but 
stabilises at a shorter scan length than GABA edited MEGA-PRESS. MEGA-PRESS 
is more accurate that both PRESS and STEAM in measuring GSH for in vivo 
measurements. This is also reflected in its in vitro quantification, where the PRESS 
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ABBREVIATIONS & SYMBOLS 
Abbreviation  Description 
1H    1Hydrogen  
2HG    2-hydroxygluterate 
ACC    Anterior cingulate cortex 
ADHD   Attention deficit/hyperactivity disorder 
ADI-R   Autism Diagnostic Interview-Revised 
ADOS   Autism Diagnostic Observation Schedule 
ALS    Amyotrophic lateral sclerosis 
ASD    Autism spectrum disorder 
ASSQ    Autism Spectrum Screening Questionnaire 
BASING   BAnd Selective INversion with Gradient Dephasing 
BW    Bandwidth 
CHESS   CHEmical Shift-Selective 
Cr    Creatine 
CRLB    Cramér-Rao lower bounds 
CSDE    Chemical shift displacement error 
CSF     Cerebro spinalfluid 
CSI    Chemical shift imaging 
DAWBA   Development and Well- Being Assessment 
DTI    Diffusion tension imaging 
DSM V Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition    
E/I    Excitatory/inhibitory 
EEG    Electroencephalography  
fMRI    Functional magnetic resonance imaging 
fMRS    Functional magnetic resonance spectroscopy 
FWHM   Full width at half maximum 
GABA   g-aminobutyric acid 
GABA+    GABA including associated macromolecules 
GAD    Glutamic acid decarboxylase 
Glx    Glutamate and glutamine 
Glu    Glutamate 
GSH     Glutathione (reduced) 
GSSG    Glutathione (oxidized) 
HERMES Hadamard Encoding and Reconstruction of MEGA-Edited 
Spectroscopy  
Hz    Hertz 
i.u.    institutional units 
M    Molar 
MHz     Megahertz 
MEGA-PRESS   MEscher-GArwood Point RESolved    
min    Minutes 
mI    Myo-inositol 
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ml    Milliliters 
MM    Macromolecules 
mm    Millimetres 
mM    Millimolar  
mmol/cm3   Millimole/cubic centimeter  
MR    Magnetic Resonance 
MRI    Magnetic Resonance Imaging 
MRS    Magnetic resonance spectroscopy 
msec    Milliseconds  
NAA    N- acetylaspartate 
NAAG   N-acetyl aspartyl glutamate  
NMR    Nuclear magnetic resonance 
OCD    Obsessive compulsive disorder 
OVS    Outer volume suppression 
ppm    Parts per million 
PRESS   Point REsolved Spectroscopy Sequence 
PRIAM  Parallel Reconstruction In Accelerated Multivoxel 
PTSD    Post traumatic stress disease 
REC Regional Committee for Medical and Health Research 
Ethics 
RF    Radiofrequency 
ROS    Reactive oxygen species 
SAD    Social anxiety disorder 
sec    Seconds 
SDQ    Strengths and Difficulties Questionnaire 
SNR    Signal to noise  
STEAM    STimulated Echo Acquisition Mode 
SVS    Single voxel spectroscopy 
T    Tesla 
TA    Acquisition time 
tCho    Total choline (phoshocholine and glycerophosphocholine) 
tCr     Total creatine (creatine + phosphocreatine) 
TE     Echo time  
TM    Mixing time 
TMS    Tetramethylsilane 
tNAA    N-acetylaspartate + N-acetyl aspartyl glutamate 
TR    Repetition time 
VAPOR   Variable power and optimized relaxation delays 
VOI    Volume of interest 
WASI    Wechsler Abbreviated Scale of Intelligence 





Symbols   Description 
µ    Magnetic moment 
w    Larmor frequency of sample compound (rad s–1)  
g     Gyromagnetic ration (rad T-1 s-1) 
B0    Static magnetic field (T) 
B1    Magnetic radiofrequency field (T or µT) 
d    Chemical shift (ppm)  
J    Scalar coupling constant (Hz) 
T1    Longitudinal relaxation time (msec or sec) 
T2    Transverse relaxation time (msec or sec) 





1.1. 1H Magnetic Resonance Spectroscopy: Basic Principles  
From being a radiology modality considered in demand but highly unnecessary and 
without any documented value by a national committee (Lønning I-rapporten) in 
1987, magnetic resonance imaging (MRI) is now regarded an invaluable diagnostic 
tool in medicine. In 1983, 200 MRI scanners were installed worldwide, and the first 
MRI machine in Norway was installed in 1986. In 1999, the number of MRI scanners 
in Norway was 39, and today the total number is 153.  
MRI magnetic field strength is measured in tesla (T). Most clinical scanners in use 
today have a field strength of either 1.5 T or 3.0 T. Scanners with ultrahigh field 
strength are available, but only used in research, where 9.4 T (1) is available for 
humans (Siemens is currently manufacturing a 11.7 T whole body MRI magnet) and 
21.0 T (2) for animals. Using a magnet with higher magnetic field strength is an 
advantage in MRI due to the higher spectral resolution and the increased signal-to 
noise ratio (SNR). However, higher field strength gives rise to more artefacts and the 
technology is more expensive. Currently almost all MRI applications takes advantage 
of 3.0 T, and for brain imaging, 3.0 T is preferred. There are currently 22 3.0 T 




Figure 1: 3.0 T GE Discovery MR750 (Milwaukee, US) with a 32-channel GE head coil. 
(Photograph by Roger Barndon) 
Magnetic resonance spectroscopy (MRS) is a MRI technique applied both in research 
and as a clinical resource tool, to detect abnormalities that may or may not yet be 
visible on conventional MRI scans. MRS is mostly used in relation to brain 
examinations, but MRS has also found its appliance in the prostate, mamma and 
musculoskeletal system. The MRS utility in the everyday clinical practice at a 
Radiology Department is limited, however, in evaluating diagnosis such as brain 
tumours and several inherited metabolic disorders (e.g. Canavans disease), its value is 
indisputable. Single voxel spectroscopy (SVS), where MRS is measured from a small 
region of interest (ROI), typically 2 x 2 x 2 cm3, is more common in clinical use than 
multi voxel spectroscopy. The advanced editing techniques (e.g. MEscher-GArwood 
Point RESolved Spectroscopy (MEGA-PRESS)) described in detail later in this thesis 
are not yet available in the clinic.  
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1.1.1. Nuclear Magnetic Resonance  
MRI is based upon the principle of nuclear magnetic resonance (NMR). The atomic 
nucleus consists of neutrons and protons which hold an intrinsic property called spin. 
Atomic nuclei with even numbers of protons and neutrons have no observable spin, 
and all the other atoms with odd numbers have a non-zero spin. All molecules with a 
non-zero spin have a magnetic moment (µ) and are NMR-active. The magnetic 
moment of the nucleus makes it behave like a small bar magnet. 
Examples of NMR-active nuclei are 1Hydrogen (1H), 13Carbon, 31Phosphorus, 
15Nitrogen, 29Silicon. 1H has a strong magnetic moment and also exists naturally in 
large amounts in biological tissue. That is why 1H is the most commonly used 
nucleus spin in both clinical and research MRI to generate MRI signals.  
When placed in an external magnetic field, two important things happen to spins.  
1) The spins precess about the magnetic field at a frequency (in the MHz range) 
defined by the Larmor equation.  
w = gB0 
Whereby g is the gyromagnetic ratio (in MHz/T) and B0 is the magnetic field 
strength (in T). The gyromagnetic ratio is a constant for a given nucleus and 
equals 42.6 MHz/T for hydrogen (1H). 
2) The spins align with the magnetic field, either parallel (low energy state) or 
antiparallel (high energy state). More precise; the presence of a strong 
magnetic field slightly favours the parallel spin orientation. The difference 
between the parallel and the antiparallel state is not that big, and the excess 
number of protons that align parallel within a 3.0 T field is only 9 per million. 
However a 2 mm x 2 mm x 5 mm voxel contains approximately 1.338 x 1021 
protons. The result is a net magnetization vector parallel to the external 
magnetic field.  
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For magnetization to generate an MR signal, it must exist in the transverse plane. 
Generation of transverse magnetization is accomplished by applying a second 
magnetic field (B1) perpendicular to the system in form of a radiofrequency (RF) 
pulse (90°) at the Larmor frequency with a specific strength (amplitude) and for a 
short period of time. When magnetization is in the transverse plane, the Larmor 
precession creates a magnetic field that can be detected by a RF coil.  
In addition to a strong magnetic field and radio wave transmitters and receivers, 
MR Scanners for in vivo human imaging also include magnetic field gradients to 
localize the signals in space, and computer software to process and analyse the 
received signals.  
Traditionally MRI is primarily concerned with the acquisition of structural tissue 
images. Varying acquisition parameters gives different tissue contrasts reflecting the 
bulk magnetic properties of the tissue they contain. The most important parameters 
are: 
• TR (repetition time): Time between excitation pulses. It reflects amount of 
recovery of longitudinal magnetization. 
• TE (echo time): The time from the centre of the 90° pulse to the centre of the 
echo 
• TI (inversion time): The time between the 180° inverting pulse and the 90° 
pulse in an inversion recovery sequence.  
• Flip angle: The angle to which the net magnetization vector is rotated to the 
main magnetic field direction during application of a RF pulse.  
1.1.2. Magnetic Resonance Spectroscopy 
Structural MRI almost always measures water and fat signals. The amounts of water 
and fat in body tissue is high (in the molar (M) range), and is consequently a good 
signal source. MRS on the other hand, acquires signals from molecules with much 
lower concentration than water and fat (in the millimolar (mM) range). The signal 
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generated in MRS is therefore of considerably smaller amplitude and it also needs to 
be separated from the significantly stronger signal from water and fat.  
Whereas MRI provides spatial maps or images of containing information regarding 
tissue density and composition, MRS is a technique that allows quantification of 
biochemical compounds to be performed in vivo. This makes MRS an important 
method for examining the cell metabolism of tissues and organs. Metabolites 
determined with MRS are present in concentrations characteristic of healthy tissue. 
However, stress, disorders or diseases may shift the concentration of metabolites. It is 
possible to display these changes, or shifts, in concentration with MRS.  
Chemical shift: 
The metabolites can be differentiated from each other since they resonate at slightly 
different frequencies based on their local chemical environments. The atomic nuclei 
are “shielded” from B0 at different levels by the electron cloud surrounding them. In 
other words, the electron reduces the magnetic field strength as experienced by the 
nucleus.  
To be able to compare spectra measured on MR scanners with different field-strength 
(e.g.: 1.5 T vs 3.0 T vs 7.0 T), the MRS frequency shift is defined relative to the 
signal of a reference molecule, tetramethylsilane (TMS), in parts per million (ppm). 
TMS has been chosen for its sharp MRS signal which does not interfere with other 
resonances signals. Resonance frequency depends on B0, but ppm is independent of 
B0.  
The chemical shift (δ) of the nuclei is defined as the difference between the Larmor 
frequency of the nuclei and the reference molecule TMS.  
The spectral display for chemical shifts shows the frequency axis from right to left. 
Signals from metabolite nuclei with stronger shielding and lower resonance 
frequency is located to the right while signals from nuclei with weaker shielding and 




Figure 2: The figure shows the direction of the electronic shielding and the resonance 
frequency in ppm in a MRS spectrum. 
Coupling: 
MR active nuclei also experience another effect; “J-coupling” also called “scalar 
coupling”. Coupling (J, measured in Hz) occurs when protons within a molecule are 
influenced by neighbouring protons through sharing of electrons.  The J-coupling 
effect is always mutual; if nucleus A affects the precession frequency of nucleus B 
through J-coupling, then nucleus B affects nucleus A. 
The result is splitting of the spectral peak, and modulation of peak phase and intensity 
as a function of TE (J-evolution/scalar-evolution). Compared to the chemical shift, J-
coupling does not depend on the strength of the external magnetic field.  
Shimming: 
Most metabolites of interest: 0.2-4.2ppm
















Good spectroscopic results require high homogeneity of the B0 field across the 
volume of interest (VOI) to ensure adequate spectral resolution and good SNR, and to 
avoid linewidth- broadening due to field inhomogeneity. For this reason, shimming of 
the main magnetic field is especially important in MRS experiments. Shimming 
involves adjusting the electrical current in shim coils making the magnetic field 
within the VOI as homogeneous as possible in the presence of the object of 
examination in the MR Scanner. 
The MRS spectrum  
The end result is the MRS spectrum which is composed of signals from multiple 
metabolites including broader bands resonances from lipids and macromolecules 
(MM), see Figure 3. Each metabolite has a unique chemical signature in the spectrum 
with a highly- reproducible frequency distribution. The relative areas under each peak 
are roughly proportional to the number of nuclei contributing to the signal.  
In the most favourable case, a peak can be validly associated with an unique 
metabolite. However, peak area measurements in MRS are complicated by resonance 
overlap, baseline distortions, and non-ideal lineshapes. Measurements will also 
depend on factors such as relaxation times, pulse sequence used, and scanner 
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hardware (e.g., receiver gain, coil loading, gradient linearity). 
 
Figure 3: MRS spectrum in the time and frequency domain. From the time domain with time 
in sec on the x-axis and signal intensity on the y axis, the MRS spectrum undergoes Fouriers 
Transform and ends up in the frequency domain where frequency in ppm is on the x-axis and 
signal intensity is on the Y axis. The final spectrum is composed of signals from multiple 
metabolites, and each metabolite is identified by a unique and highly reproducible frequency 
distribution. (Figure with minor alterations: https://www.mc.vanderbilt.edu/documents 
/fmri/files/2013_Phys352A_MRS(1).pdf) 
Lengthening TE simplifies both the baseline and the pattern of peaks in the spectra. 
Metabolites with both short and long T2 relaxation-times are observed at short TEs 
(30 msec - 35 msec). At long TEs (e.g. 144 or 288 msec), only metabolites with a 
long T2 are seen, resulting in a spectrum with primarily n-acetylaspartate (NAA), 






The MRS frequency spectrum
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Table 1: Principal brain metabolites 













*  ~ 1 mM Intracellular 
neurotransmitter 
marker 
GSH Glutathione 2.15, 2.55, 
2.93, 2.98, 
3.77& 4.56 
*  ~ 1–3 mM Main brain 
antioxidant  
mI Myoinosytol 3.6 *  ~ 4-8 mM Glial marker 




3.2 * * ~ 1-2 mM Cell membrane 
metabolism 
marker 




3.0 & 3.9 * * ~ 6-12 mM   Energy 
metabolism 
marker, often 
served as a 
reference peak 








2.1-2.5 *  ~ 14-16 mM Intracellular 
neurotransmitter 
marker 





2.0 * * ~ 7-16mM Healthy neuron 
marker 





1.1.3. Brain metabolites 
Resonance frequency, in vivo brain concentration and role of the brain metabolites 
tNAA, mI, Glx, tCr, tCho and Lac are summed up in Table 1. g-aminobutyric acid 
(GABA) and glutathione (GSH) are described more thoroughly below.  
GABA: 
GABA is the main inhibitory neurotransmitter in the mammalian brain and is present 
in more than 30-40% of all synapses; only glutamate (Glu), the main excitatory 
neurotransmitter, is more widely distributed (3). Healthy brain function relies on 
GABAergic inhibition, and understanding the role of inhibitory processes in normal 
brain function has become a core interest within basic and clinical neuroscience. The 
balance between excitatory and inhibitory (E/I) neurotransmission is tightly 
regulated. An imbalance in neurotransmitter excitation and inhibition appears to be 
involved in many of neuropsychiatric disorders such as: 
• Anxiety (4)  
• Obsessive compulsive disorder (OCD) (5) 
• Substance addiction (6)  
• Depression (7-11)  
• Schizophrenia (12), and in particular auditory hallucinations (13)  
• Primary insomnia (14)  
• Autism spectrum disorder (ASD) (15)  
And neurological diseases such as:  
• Parkinson’s disease (16)  
• Amyotrophic lateral sclerosis (ALS) (17, 18)  
• Diabetic neuropathy (19).  
The GABA molecule resonate as a quintet at 1.89 ppm, and a triplet at 2.28 ppm and 
3.01 ppm. It is usually the 3.01 ppm peak that is used for quantification. All three 
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GABA peaks are overlapped by metabolites with higher concentration, mainly Cr. 
Editing technique is one way of resolving the GABA signal from the overlapping Cr 
signal.  
An additional challenge regarding conventional GABA-editing is the co-editing of a 
signal arising from MM at 3.0 ppm (J-coupled with a resonance at 1.7 ppm). This 
signal superimposes on the GABA doublet and may contribute to as much as 60% of 
the quantified value of GABA (20).  
The concentration of GABA in the brain is relatively low, ranging from 0.5 to 
1.4 mM in healthy adults (21). A common assumption is that white matter has a 
GABA concentration that is half that of grey matter (22). It is also assumed that 
GABA levels within grey or white matter do not vary across the brain - an 
assumption which is most likely an oversimplification (23).  
GSH:  
GSH is the major cellular antioxidant important for detoxification and elimination of 
environmental toxins and free radicals that may cause damage to cellular functions by 
oxidizing lipids, proteins and DNA. In addition, GSH also plays an important role for 
the immune system and in cell differentiation, proliferation and apoptosis (24-26). 
Glutathione exists in two forms, reduced (GSH) and oxidized (GSSG). Oxidized 





Figure 4: Glutathione (GSH). A: The reduced glutathione; GSH. The thiol group serves as 
an electron donor to other molecules, such as free radicals, to neutralize them. B: The 
oxidized glutathione; GSSG. After donating an electron- two GSH have reacted to form 
GSSG.  
Oxidative stress caused by a disrupted GSH antioxidant function, has been implicated 
in the pathophysiology of numerous psychiatric and neurodegenerative disorders, 
including: 
• Schizophrenia (27-29) 
• Bipolar disorder (29-32) 
• Multiple sclerosis (33, 34) 
• Alzheimer’s disease (34) 
• ASD (35) 
• ALS (36)  
• Parkinson disease (37, 38) 
As for GABA, and other metabolites with coupled spin-systems, the GSH spectrum 
has several broad low-amplitude signals that are not fully resolved from the other 
metabolites in the in vivo spectrum. Again, spectral editing schemes can be applied. 
The GSH molecule resonate at 2.15 ppm, 2.55 ppm, 2.93 ppm, 2.98 ppm, 3.77 ppm 
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and 4.56 ppm.  The concentration of GSH in the healthy brain is 1–3 mM (39), with 
higher levels in grey matter than white matter (40, 41). 
1.1.4. MRS acquisition methods 
A more detailed description of the MRS sequences applied in the four studies are is 
found in the methods section (3.1) 
Single voxel spectroscopy (SVS) 
SVS measure the MRS spectrum of a single selected small VOI. Three mutually 
orthogonal slices are stimulated sequentially for localisation, and the VOI is the result 
of the intersection of the three slices. Only the spins in this voxel are measured.  
The two most common pulse sequences for excitation and localization in SVS are 
STimulated Echo Acquisition Mode (STEAM) and Point REsolved Spectroscopy 
Sequence (PRESS). The sequences differ in the radiofrequency pulses used to 
generate echo’s (Stimulated echo in STEAM and spin echo in PRESS), while the 




Figure 5: Single voxel vs Multi-voxel MRS. A: Multi-voxel chemical shift imaging (CSI): 
more time consuming, but better assessment of entire larger lesions and spatial resolution for 
smaller organs and lesions.) Not (yet) available for Glu, GABA and GSH. B: Single voxel 
spectroscopy (SVS): Most widely used, fast and easy, but limited application for large or 
inhomogeneous lesions.  
Multi-voxel chemical shift imaging (CSI) 
CSI have a larger total coverage area and a higher spatial resolution than SVS 
sequences, however there are several disadvantages with this technique, including; 
1) Both the pre-scan preparation for the technician and the imaging time is 
longer. 





3) The SNR and spectral quality for each individual voxel is lower. 
4) There is a substantial spectral cross voxel contamination. About 24 % (42) of 
the signal in every voxel in a 2D CSI acquisition derives from its neighbour 
voxels.  
5) Editing sequences for measuring substances like GABA and GSH are yet not 
available for CSI. 
CSI is based on a repetition SVS with added spatial phase encoding, and can be either 
2D or 3D. In a true 3D CSI, the number of phase encoding steps equals the total 
number voxels acquired. A matrix of 8x8x8 voxels with a TR of 2.0 sec will take 
2x8x8x8 = 1024 sec, or approximately 17 min to perform. 
MRS editing techniques 
There are three approaches to separate spectrally overlapping resonances: 
1) Increasing the B0 and with this making the signals stronger and more spread 
out (higher spectral resolution).  
2) Adding a second frequency dimension to the MR acquisition allowing the 
signals more space to spread out.  (2D spectroscopy techniques such as 
JPRESS and COSY). 
3) Reducing the information content of the spectrum by editing techniques. 
The third strategy is referred to as “editing” the spectrum. All editing sequences have 
two features in common: the localisation of signal (usually PRESS), and a 
mechanism for reducing the information content of the spectrum. The most common 
editing approaches takes advantage of known J-coupling relationships within 
molecules of interest to separate from the overlapping and more concentrated 
molecules, e.g.: MEGA-PRESS (43) and BAnd Selective INversion with Gradient 
Dephasing (BASING) (44). 
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Metabolites that can be edited include GABA, GSH, ascorbic acid, Lac, aspartate, N-
acetyl aspartyl glutamate (NAAG), 2-hydroxygluterate (2HG), Glu, glycine and 
serine. 
Recent development has seen advanced editing approaches that can separate not only 
one, but two or even more J-coupled metabolites simultaneously. Double MEGA-
editing is such an example (45).  A Hadamard encoding scheme (Hadamard Encoding 
and Reconstruction of MEGA-Edited Spectroscopy (HERMES)) (46) in the 
frequency domain allows the simultaneous acquisition of even multiple metabolites 
within a single editing sequence. The method has been applied for the measurement 
of NAA, NAAG and aspartate, (47) GABA and GSH (48). It is also possible to 
combine HERMES with a dual voxel excitation scheme (Parallel Reconstruction In 
Accelerated Multivoxel (PRIAM)) and acquire two J-coupled metabolites from two 
brain regions simultaneous (49) which is equivalent to a fourfold net acceleration.  
1.2. Autism Spectrum Disorder 
1.2.1. Background 
ASD is a developmental disorder defined by impaired social communication and 
interaction, and by restricted, repetitive patterns of behaviour, interests or activities 
(50). The ASD phenotype comprises a spectrum of symptoms varying in their 
presentation, the course and outcome, and in their responses to therapy. The 
estimated prevalence of ASD in the Norwegian population ranges from 0.44 – 0.87% 
(51, 52) with 4-5 times as many boys as girls diagnosed with the disorder (53).  
No single cause has been identified in ASD, and, given the complexity of the disorder 
and the wide variety of symptoms and the varying severity, there are probably many 
interacting causes. What we do know for certain is that ASD is highly heritable. The 
relative risk of a second child having this diagnosis is 20-50 times higher than the 
population based rate (54). For ASD in general, from twin and family studies, the 
heritability estimates have been determined to be around 90% (55). Parents and 
siblings often show mild manifestations of ASD (~ 20-45%), including delayed 
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language, difficulties with social aspects of language, delayed social development, 
absence of close friendships, and a perfectionist or rigid personality style (56). 
Children with ASD show less attention to social stimuli, smile less and have less eye 
contact. They often fail to develop age-appropriate peer relationships, and struggle 
with the specific characteristics of social boundaries that are mostly invisible and 
context dependent. Another symptom is extreme resistance to change. Children with 
ASD usually prefer established behaviour and set environments. As a reaction to 
stress they can show a wide range of stereotypic behaviours and movements. The 
unusual social development normally becomes apparent early in childhood and 
clinical signs are usually present by age 3 years (50).  
There are a number of comorbidities and symptom complexes found in patients with 
ASD, and these create an extra challenge for individuals with ASD and their families, 
educators, and health professionals. 
A study by Gjevik et al (57) examining 71 6- to 18-year old Norwegian children with 
ASD for other child psychiatric disorders found that 72 % of participants had at least 
one comorbid disorder, and 41 % had two or more. The most common overlaps were 
for anxiety disorders diagnosed in 42 % of the children and attention-
deficit/hyperactivity disorder (ADHD) diagnosed in 31 % of the children. (Anxiety 
disorder including specific phobias, social phobia and obsessive-compulsive 
disorder). Depressive disorder was diagnosed in 10 % of the children and tics were 
diagnosed in 11 % of the children. These results are consistent with other similar 
studies (58). The question is whether these comorbidities are true comorbidities, or 
just a part of the ASD syndrome.  
An estimated 30 % of ASD patients also have epilepsy, and as many as 85 % of 
children with ASD have subclinical epileptiform activity recorded on scalp 
electroencephalography (EEG)  (59, 60).  
There are no definitive biological markers of ASD and the diagnosis is based on the 
assessment of behaviour patterns and the observations of the child’s expressions and 
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demeanour by applying different mapping tools. Examples of such tools are the 
Autism Diagnostic Observation Schedule (ADOS) and the Autism Diagnostic 
Interview-Revised (ADI-R). In Norway, the diagnostic evaluation is done by a 
multidisciplinary team consisting amongst others psychologist and psychiatrist.   
ASD is considered a lifelong chronic disorder, and there exists no known cure. At 
present, the main goal for treatment is to reduce associated clinical and cognitive 
impairments in order to lessen family stress and maximize the individuals ability to 
function in its environment (61).  
1.2.2. ASD & MRS 
Despite the promise of MRS in understanding the pathophysiology of ASD through 
measuring in vivo biochemical and metabolite concentration levels, the scientific 
literature in this area is replete with contradictory results.  A summary of the main 
findings in the ASD & MRS literature with focus on GABA, Glu and GSH follows. 
GABA and Glu 
GABA and Glu MRS applications have been directed towards addressing the hyper-
glutaminergic (62) or hypo-GABAergic (63) dysfunction hypothesis of ASD.  
The literature indicates that an E/I imbalance in persons with ASD could lead to 
excessive stimulation of the glutamate system resulting in “excitotoxicity" in regions 
of the brain responsible for language, social interaction, and multisensory perception 
(64, 65). The increased prevalence of seizure disorders in ASD could also be 
explained by such neural hyper excitability (59). 
Several studies provide evidence for cellular abnormalities that may contribute to E/I 
imbalance in ASD; animal models (66-68), post-mortem studies (69-75) and studies 
of gene function and expression (54, 76, 77).  
The signals from Glu are difficult to distinguish from glutamine even at high-field 
scanners, short TE and long acquisition time, and different editing techniques, thus 
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the two metabolites are usually measured and quantified together as Glx (78). 
(Included in the Glx signal is also minor contributions from GABA and GSH). There 
are no compelling evidence in support of changed Glx levels in ASD, both higher and 
lower Glx levels have been reported (79). However, in older groups with ASD, Glx 
levels tend to be increased, while younger groups with ASD tend to have reduced Glx 
or no changes (80).  
Four studies (not including the present study in the thesis) have been published 
measuring GABA levels in children with ASD at 3.0 T applying the MEGA-PRESS 
editing technique. Reduced GABA/tCr concentration in ASD compared to typically 
developing controls (TD) (81-84) were reported in the following ROIs; frontal lobe, 
left motor cortex, left auditory cortex and right sensorimotor cortex, and no 
significant difference in GABA/tCr were found in ROIs in the left auditory cortex 
and the middle occipital cortex (82, 84). 
GSH: 
Another pathophysiological hypothesis of ASD is the redox/methylation theory 
suggesting an imbalance between oxidative stress and the antioxidant system leading 
to neuronal damage in genetically predisposed individuals (85). Disturbance in GSH 
homeostasis has been found in other psychiatric and neurological disorders, including 
schizophrenia (29, 86), bipolar disorder (87), Parkinson’s disease and Alzheimer’s 
disease (88, 89). The redox/methylation theory is supported by reduced glutathione-
mediated redox status in blood samples (90-94) and post-mortem findings (35, 95) in 
individuals with ASD. 
To this date, only two MRS studies measuring GSH with adequate techniques have 
been published (35, 96). One study found reduced GSH levels in the cerebellum and 
temporal cortex of the brains of individuals with ASD compared with age-matched 
control subjects, with no differences in the frontal, parietal and occipital cortices (35). 
While the other study found no group differences in GSH concentrations in either the 
dorsolateral prefrontal cortex and the dorsal ACC (96). Two other studies, Durieux 
2015 (97) and Endres 2017 (96), found no group differences in GSH concentrations 
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in either the basal ganglia, the dorsomedial prefrontal cortex, the dorsolateral 
prefrontal cortex and the ACC. However, the MRS data in these studies were 
acquired with a simple PRESS sequence which is probably not adequate for 
measuring GSH, and the results are most likely not to be trusted.   
tNAA, tCr, tCho, mI: 
Several studies have shown decreased tNAA, tCr, tCho and mI levels (98). There is 
however inconsistency in the literature and the results vary. Some studies even found 
a substantial increase in the above-mentioned metabolites. Widespread reduction of 
tNAA, tCr, tCho and mI in ASD may reflect dysfunction, loss or immaturity of 
neurons (99) and glial cells (100) and reduced axon density (101). 
It should be mentioned that a field-strength of 1.5 T has been applied in 80 % of these 
MRS investigations. MR systems at 3.0 T have several advantages over 1.5 T 
systems in MRS when it comes to increased SNR and better spectral resolution, and 
some challenges such as larger chemical shift and higher sensitivity to magnetic 
susceptibility effects. These differences make it difficult for a direct comparison 




2. SPECIFIC BACKGROUND AND AIMS OF THE 
STUDY  
2.1. Specific background 
Neurological and psychiatric disorders are now recognised as leading causes of 
morbidity and disability, and rank among the most costly disorders to affect humans 
(102). The underlying mechanisms of many of these disorders are largely unknown, 
and identifying the underlying pathophysiology is imperative and may lead to major 
health benefits. Evidence implicate that an imbalance in excitatory Glu and inhibitory 
GABA activity in the brain may be a shared pathophysiological mechanism in 
disorders, such as ASD and schizophrenia. Another metabolite that has come in focus 
lately is the powerful brain antioxidant GSH. A decrease in cell GSH levels results in 
increased vulnerability to oxidative stress, and is thought to be implicated in the 
aetiology of inflammatory, immune- and neurodegenerative diseases.  The advanced 
MRS technique MEGA-PRESS provides the opportunity to investigate both GABA 
and GSH levels non-invasively in the brain. The same MRS technique may also be 
applied for the measurements of Lac and 2HG – metabolites that are highly 
interesting in clinical settings.  
It is necessary to validate the MEGA-PRESS editing technique for both GABA and 
GSH to be able to trust the measurements we achieve. This has not always been done 
adequately in the past years and the results which we refer from previous research are 
therefore potentially not reliable. Unvalidated MRS techniques will contribute to 
MRS’s poor reputation by some clinicians, and might even prolong the time until 
some of these advanced MRS techniques are introduced to clinical practice.  
This project involves characterisation of neurochemical changes associated with 
ASD, by applying the GABA edited MEGA-PRESS technique. In addition, 
reproducibility studies of GABA and GSH using the same technique have been 
performed for the value of future studies. The projects also include phantom studies 
for validating data acquisition and data analysing. MRS processing and analysing 
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tools have been developed and improved parallel to the project both within the fMRI 
group but also with international co-operators.  
2.2. Aims of the study 
PAPER I:  GABA edited MEGA-PRESS in ASD;  
In the first publication, MRS was applied to children with ASD and healthy controls 
using the PRESS and MEGA-PRESS sequences in a voxel placed in the left ACC. 
The aim was to look for imbalances in metabolites in the ASD group and to replicate 
previously published results regarding the Glu/GABA E/I imbalance theory.  
PAPER II: GABA edited MEGA-PRESS reproducibility;  
In the second study, the aim was to validate GABA edited MEGA-PRESS results in a 
replication-study in a group of healthy adult volunteers. The reliability of metabolite 
concentration estimates was systematically examined both within- and between-
measurements by increasing scan time. The effect on reproducibility of voxel 
placement and application of different analysing tools were also tested. 
PAPER III: The GSH “Christmas phantom” study; 
In the third study, the aim was to measure changes in GSH concentration using the 
PRESS and MEGA-PRESS sequences by tracking the natural oxidation of GSH in a 
phantom. The accuracy of the two sequences would also be evaluated.   
PAPER IV: GSH edited MEGA-PRESS reproducibility;  
In the fourth study, the aim was to validate GSH edited MEGA-PRESS by a similar 
fashion as the GABA reproducibility study. A short TE PRESS and STEAM 
sequence were also included to look at how well GSH measurements from the three 
MRS techniques agree. An additional element in this study is that both males and 
females were included in order to look at gender differences.  
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3. MATERIALS AND METHODS  
The different MRS techniques applied in the four papers are described in details in 
section 3.1. Lipid suppression, water suppression, data pre-processing and spectrum 
quality control are also addressed in this section. Section 3.2 contains a description of 
participants and data collection for the four studies including an account of the MR 
protocol. Section 3.3 describes the statistical methods used.   
3.1. MRS 
PRESS 
The single voxel PRESS sequence uses one slice selective 90˚ pulse followed by two 
slice-selective 180˚ pulses to create a spin echo.  
The pulse sequence structure in the PRESS sequence results in relative high 
minimum achievable TE, since multiple RF-pulses and waiting for the spin echo’s 
takes time.  TEs of 30-35 msec are routinely used in PRESS. Long TEs is, however, 
applicable for measuring metabolites with a long TE, and TE of 144 msec is 
particularly useful as it inverts Lac at 1.3 ppm.  
There exists a potential for tissue heating in the PRESS sequence. This is caused by 
the multiple 180º-pulses which in some instances might exceed the specific 
absorption rate (SAR) limit. 
A standard PRESS sequence (TE = 35 msec) was included in the ASD study to 
measure the metabolites tNAA, tCr, tCho and mI. PRESS (TE = 30 msec) was also 
included in the two GSH- studies to test the accuracy and reproducibility of PRESS 




Figure 6: The PRESS sequence. The PRESS sequence consists of a slice selective 90° 
excitation pulse and two 180° refocusing pulses. The time interval between the two 180° pulses 
are TE/2. The time between the 90° pulse and the first 180° pulse as short as possible, but 
sufficiently long to allow the gradient pulses to be played put. RF = Radio Frequency pulse, 
x= gradient in x-plane, y = gradient in y-plane and z = gradient in z-plane. Courtesy of Allen D. Elster, MRIquestions.com. 
STEAM 
The single voxel STEAM sequence consists of three selective 90° pulses to produce a 
stimulated echo. STEAM allows for short TEs (down to ~ 7 msec) making it possible 
to detect short T2 metabolites such as Glu, GSH and mI. The use of 90˚ pulses allows 
for sharper slice profile, higher bandwidth, and lower tissue energy 
deposition.  However, the STEAM signal is only 50 % as large as for PRESS. 
In the GSH reproducibility study, a short TE STEAM sequence (TE = 7 msec) was 
applied in order to examine the GSH reproducibility compared to a MEGA-PRESS 




Figure 7: The STEAM sequence. The STEAM sequence consists of three 90° slice selective 
pulses. The interval between the second and third pulses, mixing time (TM), is kept to a 
minimum. T2 decay does not occur during TM, and TM is therefore not included in TE. RF = 
Radio Frequency pulse, x= gradient in x-plane, y = gradient in y-plane and z = gradient in z-plane. Courtesy of Allen D. Elster, MRIquestions.com. 
The main difference between STEAM and PRESS is that the spin-echo-based PRESS 
sequence has twice the SNR, while STEAM has the ability to obtain shorter TEs 
(103). Short TE STEAM is preferable for observing resonances with shorter T2s, 
while long TE PRESS (with its superior SNR) should be used for resonances with 
longer T2s (such as tCho, tCr, tNAA and Lac). 
MEGA-PRESS 
As mentioned in section 1.1.3, MRS signals from molecules such as GABA and GSH 
are overlapping and obstructed in conventional brain MRS by signals from other 
compounds which are present at much higher concentrations. In order to obtain 
signals from GABA and GSH, the spectral editing technique of MEGA-PRESS can 
be applied. The method takes advantage of J-coupling properties in the metabolite of 
interest and suppresses signals from unwanted compounds. A description of GABA 





Figure 8: The MEGA-PRESS sequence: The MEGA-PRESS sequence consists of the 
acquisition of two datasets (“ON” and “OFF”). Two frequency-selective editing pulses are 
incorporated into a single voxel PRESS sequence. For the “ON” spectra the editing pulses 
are applied at 1.9 ppm for GABA editing and 4.56 ppm for GSH editing, while for the "OFF” 
spectra the editing pulses are omitted (or more commonly, applied at a frequency that has no 




Figure 9: The GABA molecule 
In GABA edited MEGA-PRESS, the editing inversion pulses are applied to the C-3 
protons of GABA at 1.9 ppm. Due to the J-coupling the C-4 protons of GABA at 
3.02 ppm are affected while other metabolite peaks like the strong Cr peak remain 
unaffected. This is called the EDIT-ON spectra. In a second acquisition scheme 
called EDIT-OFF, the same pulse is applied symmetrically to the other side of the 
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water peak at 7.5 ppm (4,7 ppm + (4.7 ppm – 1.9 ppm)), this is done to reduce 
baseline artefacts in the edited spectrum. The inversion pulse in the EDIT-OFF 
spectra does not affect the J-coupling in the GABA molecule, and the J-coupling 
evolves freely throughout the TE. EDIT-ON and EDIT-OFF spectra are acquired in 
an interleaved fashion several times, a total of 256 spectra (128 EDIT-ON spectra and 
128 EDIT-OFF spectra) or more is common. 
 
Figure 10: Schematic diagram of MEGA-PRESS editing for GABA (a) Editing pulses applied 
at 1.9 ppm modulate the shape of the GABA signals at 3.0 ppm (b). Subtracting scans acquired 
without these pulses (labelled OFF) from scans acquired with the editing pulses (ON) removes 
overlying Cr signals from the edited spectrum, revealing the GABA signal in the difference 
spectrum (labelled DIFF). (b) The effect of editing pulses on signals at 3 ppm signal is  shown. 
(Mullins et al., 2014 NeuroImage, reprinted with permission.) 
The EDIT-ON and EDIT-OFF spectra are then summed up, and the resulting 
difference spectra is derived from the difference between the two. The difference 
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spectrum does not have the strong singlet signal from Cr, allowing quantification of 
the GABA peak at 3.02 ppm. Important to notice is that this peak also includes 
signals from coedited macromolecules (MM) and the measured signal is therefore 
considered as GABA+ (GABA + MM). 
GSH 
In GSH edited MEGA-PRESS, the editing pulses in EDIT-ON are applied to the 
cysteine alpha proton at 4.56 ppm. The observed signal due to J-coupling originates 
from the beta protons at 2.93 ppm and 2.97 ppm. 
 
Figure 11: The GSH molecule 
In GSH edited MEGA-PRESS, the editing pulse is very close to water (editing pulse: 
4.56 ppm, water peak: 4.68 ppm), so applying the EDIT-OFF pulse symmetric to 
water gives little meaning, and could even partly affect the cysteine alpha proton at 
4.56 ppm and ruin the difference spectra. In the GSH reproducibility study – the 
editing pulse in the OFF spectra was set to 20 ppm- and by this not affecting any of 




Figure 12: GSH edited MEGA-PRESS: Average ON spectrum minus average OFF spectrum 
gives a difference spectrum with a GSH peak ~ 3.0 ppm. The difference spectrum has been 
line broadened with a 5 kHz exponential function for visualization only.  
The ON and OFF spectra are generally collected interleaved to limit the impact of 
participant and hardware instabilities. The editing efficiency is a measure of how 
much of the theoretically observable signal can be measured. The editing efficiency 
for GABA edited MEGA-PRESS at TE 68 msec is about 0.4 - 0.5 (22, 104) and close 
to 0.74 (105) for GSH edited MEGA-PRESS at TE 131 msec.  
Lipid suppression:  
Fat from voxels obtained near the scalp tissue can distort the baseline of the MR 
spectra so that metabolites cannot be detected. Lipids resonate at 1.3 ppm.  
The most common method to eliminate unwanted fat signal is using outer volume 
suppression (OVS) techniques. OVS bands utilizes spatially (but not frequency) 
selective pulses and dephasing gradients to reduce or eliminate signals from all 





Figure 13: (A) MRS spectrum with lipid contamination & (B) OVS bands: (A) A short TE 
PRESS spectra with severe lipid contamination. Head movement has caused the voxel to partly 
cover a region with lipids. (B) An illustratory example of how OVS bands can be applied for 
lipid suppression in single voxel spectroscopy.  
Water suppression 
The most commonly used method for water suppression is to apply water peak 
frequency selective RF pulses prior to MRS signal excitation to minimize the 
longitudinal magnetization of water at the time of excitation. CHEmical Shift-
Selective (CHESS) (106) RF pulses tip the longitudinal magnetization of water into 
the transverse plane, where it gets dephased by a gradient crusher while the 
magnetization of other frequencies remains unaffected. Multiple CHESS pulses with 
optimized flip angles and delays can be used to give good water suppression over a 
range of B1 field strengths (B1 inhomogeneity) values and water T1 relaxation times 
(which is important for the suppression of both brain water and cerebrospinal fluid 
(CSF)).  
Other examples of water suppression  are the Water suppression Enhanced through 
T1 effects (WET) (107) scheme, which employs three to four CHESS pulses of 
optimized flip angle and the VAriable POwer and optimized Relaxation delays 




Water suppression in STEAM, PRESS and MEGA-PRESS sequences in GE systems 
is currently done with three CHESS pulses at three different flip angels. (Default flip 
angles: 105°, 80°, 145°.) 
Averaging is a process of repeating the sequence of RF pulses, gradient pulses and 
the signal acquisition a specified number of times, in order to add more signal. 
Adding signal increases the SNR in proportion to √N where N is the number of 
repetitions that are averaged. A substantial number of repetitions, typically 64, 96, 
128, 192, 256 or more, is necessary to obtain a high quality averaged spectrum. 
Several different expressions have been used in the MRS literature to describe the 
number of averages applied in the acquisition of the MRS spectra. Scans, averages, 
sums of averages, sums of signals, repetitions all mean the same thing. In sequences 
like PRESS and STEAM, the nomenclature is fairly straightforward. In MEGA-
PRESS, however, it is important to specify whether one means e.g. 256 ON + 256 
OFF repetitions or 256 repetitions in total.   
Data pre-processing and spectrum quality control  
Data pre-processing in MRS include: 
• Coil combination (phase correct and combine data from the individual coils 
from either the 8- or the 32- channel phased array receive head coil). 
• Automatic frequency and phase correction of the single-scan data. 
• Water removal. 
• Zero-filling (to improve resolution). 
• Elimination of residual eddy current effects (109).  
• Applying an apodization filter (exponential line broadening) to remove noise 
from the detector channels.  
Some steps are done in the time domain while others are done in the frequency 
domain, and this varies in the different software packages.  
If LCModel is to be used for analysis, the apodization filter should not be applied and 
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the data needs to be in the time domain. Fourier’s transformation and the reverse 
Fourier’s transformation can be applied to transform between the frequency and the 
time domain data.  
 
Figure 43: MRS Pre-processing: (A) Raw time domain data. (B) Time domain data after 
zerofilling and apodization. (C) Data in the frequency domain, a quite solid water peak 
remains even after water suppressed MRS acquisitions. (D) The finally processed MRS 
spectrum in the frequency domain.  
Data are visually inspected for spectral artefacts (e.g. non-constant baselines and 
subtraction errors in MEGA-PRESS,) and unwanted signals (especially lipid 
contamination). Wide peak shapes reflect poor shimming or patient motion. There 
should be no trouble separating the main Cho (at 3.2 ppm) and Cr (at 3.0 ppm) peaks.  
Quality parameters for data acquisition are: 
Time (sec) Time (sec)
5 4 3 2 1 0
Frequency (ppm)







Signal-to-noise ratio (SNR): The amplitude of the metabolite over the amplitude of 
the noise. The minimum acceptable SNR in an in vivo spectrum is usually set to 10. 
The different analysing packages have different approaches on defining the noise 
signal. In Gannet, the modelled tNAA signal in the averaged OFF spectrum is divided 
by the SD of the detrended noise signal between 10 and 11 ppm.  
Spectral linewidth: How broad the peaks are in the resulting spectra- the full-width 
half-maximum (FWHM). After shimming, a spectral line width FWHM < 8-12 Hz is 
considered acceptable values in in vivo spectrum depending on the region examined. 
The different software packages have different approaches also here. In Gannet, the 
spectral linewidth from the modelled unsuppressed water signal or a modelled 
metabolite (tCr/tNAA/GABA) signal are measured directly.  
Estimation of fitting reliability are: 
The appearance of the residuals, the quality of the baseline fit and % Cramer-Rao 
Lower Bound (CRLB) are estimates on how well the MR spectra are fitted. CRLB 
are error estimates of the quantitative fitting procedure and includes the effects of the 
SNR and the inherent limits of the fitting model. CRLB < 20 % is considered 
acceptable.  
3.2. Participants and Data Collection 
3.2.1. PAPER I:  GABA edited MEGA-PRESS in ASD  
Participants 
The study was approved by the Regional Committee for Medical and Health 
Research Ethics in Western Norway (REK 2011/565). Written informed consent was 
retrieved from the boy’s parents or legal representatives.  
Initially, 20 boys fulfilling the ASD diagnosis criteria according to the Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria (110) were 
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included. 30 age matched controls (boys) were recruited from the National Registry 
as control participants.  
Trained psychology students assessed all participants with the two sub-test of the 
Wechsler Abbreviated Scale of Intelligence (WASI) (111) . The ASD section of the 
structured interview questionnaire Development and Well- Being Assessment 
(DAWBA) was performed in order to exclude presence of ASD symptoms in the TD 
group (112). A mental health screening questionnaire from a local Child Study 
including the Strengths and Difficulties Questionnaire (SDQ) (113) and the Autism 
Spectrum Screening Questionnaire (ASSQ) (114) were also included. 
Exclusion criteria in both groups were braces (for the MR investigation), genetic 
abnormalities and gestation age <36 weeks. In addition, epilepsy and autistic traits 
and other neuropsychiatric disorders were exclusion criteria in the TD group.  
Acceptable MEGA-PRESS/ PRESS spectra were obtained in 14 boys in the ASD 
group and 21/24 boys in the TD group. (Six boys in each group were excluded for 
various reasons. See the Paper I for more details.) 
See Table 2 for a description of the participants, including age, and ASSQ-score. 
(ASSQ-score is only applicable for the ASD group.) 
Table 2: Demographics 




ASD PRESS 14 10.2 ± 1.9 23.5 ± 8.4 
 MEGA-PRESS 14 10.2 ± 1.9 23.5 ± 8.4 
TD PRESS 24 10.2 ± 1.8 NA 




Brain MRI scans were acquired using a 3.0 T GE Signa HDXt MR scanner 
(Milwaukee, USA) equipped with an 8-channel head coil. The following MR 
protocol was applied:  
1) 3D FSPGR T1 weighted anatomical scan. Number of slices = 188, slice 
thickness = 1.0 mm, repetition time (TR) = 7.8 msec, TE = 2.95 msec, 
inversion time (TI) = 500 msec, field of view = 260 × 260 mm2, flip angle 
= 14°, matrix = 192 × 192 giving a total acquisition time (TA) = 7:28 min.  
2) PRESS with TR = 1500 msec and TE = 35 msec, 128 repetitions giving 
TA = 3.48 min.  
3) MEGA-PRESS with TR = 1500 msec and TE = 68 msec, 128 paired 
repetitions of 4096 datapoints (TA ~ 7 min) at 5 kHZ spectral width with a 
phase cycling of 8 paired repetitions. A 16 msec sinc weighted Gaussian 
editing pulse was applied at 1.9 ppm (ON) and 7.46 ppm (OFF) in interleaved 
scans. 
Both the PRESS and MEGA-PRESS acquisitions were obtained from a 21 ml voxel 
in the left ACC.   
3.2.2. PAPER II: GABA edited MEGA-PRESS reproducibility  
Participants: 
Twenty-one healthy male volunteers (age 32 ± 6 (SD)) were recruited in accordance 
with local ethical guidelines. Written informed consent was retrieved.  
Participants were instructed to abstain from caffeine, alcohol, and nicotine, exercise 
and sex for the twelve hours prior to each MR examination due to possible influences 
on GABA levels. 
MR protocol: 
Brain MRI scans were acquired using a 3.0 T GE Discovery MR750 (Milwaukee, 
US) with a 32-channel GE head coil. The following MR protocol was applied: 
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1) 3D FSPGR T1 weighted anatomical scan. Number of slices = 188, slice 
thickness = 1.0 mm, TR = 7.8 msec, TE = 2.95 msec, TI = 450 msec, field of 
view = 256 × 256 mm2, flip angle = 12°, matrix = 256 × 256 giving 
TA = 7:10 min. 
2) MEGA-PRESS with TR = 1800 msec and TE = 68 msec, 328 paired 
repetitions of 4096 datapoints (TA~20 minutes) at 5 kHZ spectral width with a 
phase cycling of 8 paired repetitions. A 20 msec sinc weighted Gaussian 
editing pulse was applied at 1.9 ppm (ON) and 7.46 ppm (OFF) in interleaved 
scans.  
Two voxel placements; one from a 21 ml volume in the middle ACC and the other 
from a 22 ml volume in the left inferior frontal gyrus (Broca’s region). The order of 
the two brain regions was randomized (balanced), to avoid any bias. 
All participants were scanned twice with identical protocols, at exactly the same time 
of the day, one week apart.  
In vitro phantom scans were included as an indicator for performance under ideal 
conditions. The phantom MEGA-PRESS acquisitions were performed using the same 
sequence parameters as for in-vivo scans, but with a smaller voxel size (12 ml) 
The metabolite solution was based on the GE “braino” MRS-HD-Sphere 
spectroscopy phantom used in Schirmer and Auer (115), with the following 
metabolite concentrations: 10 mM NAA, 10 mM Cr, 3 mM Cho, 7.5 mM mI, 10 mM 
Glu, 5 mM Lac, with the addition of GABA at a concentration of 2.0 mM. 
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3.2.3. PAPER III: The GSH “Christmas phantom” study.  
Phantom preparation: 
The metabolite solution was based on the GE “braino” MRS-HD-Sphere phantom 
used in Schirmer and Auer (115) with the following metabolite concentration: 
12.5 mM NAA, 10.0 mM Cr, 3.0 mM Cho, 7.5 mM mI, 12.5 mM Glut, 5.1 mM Lac, 
2.0 mM GABA and 3.0 mM GSH. 
MR protocol:  
MRI scans were acquired using a 3.0 T GE Discovery MR750 (Milwaukee, US) with 
an 8-channel GE head coil. The following MR protocol was applied: 
1) MEGA-PRESS with TR = 1800 ms, TE = 131 ms and 328 paired repetitions 
(328 ON and 328 OFF scans) of 4096 datapoints (TA = 20:24 min) at 5 kHz 
spectral width, phase cycling of 8 paired repetitions, 20 ms sinc weighted 
Gaussian editing pulse was applied at 4.56 ppm (ON) and 20 ppm (OFF) in 
interleaved scans.  
2) PRESS with TR = 3000 ms and TE = 30 ms, 256 repetitions giving a TA of 
14:00 min.  
In both acquisitions, a fixed voxel size was 35 x 20 x 25 mm3 was used. The voxel 
was positioned in the centre of the phantom using a T1 weighted image acquired 
before the MRS acquisition. A total of 122 MEGA-PRESS and PRESS spectra were 
acquired during a time period of 11 days. One year follow-up acquisitions with the 
same sequence parameters were performed on the same phantom. The decaying GSH 
signals measured from both MEGA-PRESS and PRESS data were then modelled in 
Matlab. 
Acquisitions were also made on a similar phantom without GSH and a pure GSSG 
phantom. The phantom without GSH was used as a zero reference to make sure that 
neither MEGA-PRESS nor PRESS quantified any GSH when no GSH was present. 
The pure GSSG phantom was used to establish T2 relaxation time for GSSG. 
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3.2.4. PAPER IV: GSH edited MEGA-PRESS reproducibility  
Participants 
The study was approved by the Regional Committee for Medical and Health 
Research Ethics in Western Norway (REK 2017/516). 41 healthy volunteers (aged 25 
± 4.2 (SD), twenty females) were recruited. Written informed consent was retrieved.  
Participants were instructed to abstain from strenuous exercise 6 hours and alcohol 
and nicotine twelve hours prior to each MR examination due to possible influences 
on GSH levels. 
MR protocol: 
Brain MRI scans were acquired using a 3.0 T GE Discovery MR750 (Milwaukee, 
US) with a 32-channel GE head coil. The following MR protocol was applied: 
1) 3D FSPGR T1 weighted anatomical scan. Number of slices = 188, slice 
thickness = 1.0 mm, TR = 8.2 msec, TE = 3.2 msec, TI = 600 msec, field of 
view = 256 × 256 mm2, flip angle = 8°, matrix = 256 × 256 giving 
TA = 11:44 min. 
2) MEGA-PRESS with TE = 131 msec and TR = 1800 msec, 192 paired 
repetitions of 4096 datapoints (TA = 12:14 min) at 5 kHZ spectral width with 
a phase cycling of 8 paired repetitions. A 16 msec sinc weighted Gaussian 
editing pulse was applied at 4.56 ppm (ON) and 20 ppm (OFF) in interleaved 
scans.  
3) PRESS with TE = 30 msec and TR = 1800 msec, 128 repetitions giving 
TA = 4:34 min.  
4) STEAM with TE = 7 msec, TR = 1800 msec and TM = 8.784 msec, 128 
repetitions giving TA = 4:34 min.  
MEGA-PRESS, PRESS and STEAM were performed at two different voxel 
placements; a 20.6 ml volume in the middle OCC and a 20.6 ml volume in the left 
ACC. The order of the two brain regions was randomized (balanced), to avoid any 
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bias. All participants were scanned twice with identical protocols, at exactly the same 
time of the day, one week apart. 
3.3. Statistical Methods 
Demographic, ASSQ, Intellectual ability (WASI) and MRS data were analysed using 
SPSS (version 12.01) (IBM Corp. USA) statistical analysis software package.  
Normally distributed data were analysed with either Student’s t-test. When the data 
were not normally distributed, a log-transformation was performed, and if the data 
were still not normally distributed, the nonparametric Mann-Whitney U test was 
applied.  
Coefficients of variation (CVs) analysis were performed with Excel (Microsoft 
Office 2010), and effect size and power analyses were acquired with G*Power 3.1. 
All significance levels were set to 0.05. 
A time window approach was applied in both the GABA and the GSH reproducibility 
analyses. The acquisitions were subdivided to produce datasets equivalent to various 
shorter scan lengths (16, 32, 48, 64… and 192 paired repetitions). These datasets 
were then applied for both the within-and between-session analyses.  
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4. MAIN RESULTS 
PAPER I:  GABA edited MEGA-PRESS in ASD;  
There was a significant negative correlation in the ASD group between ASSQ and 
GABA levels, however no significant difference between ASD and typically 
developing controls in GABA levels was found. 
PAPER II: GABA edited MEGA-PRESS reproducibility;  
Increasing the number of repetitions showed improvements for within- and between-
session reproducibility up to about 218 repetitions. (CV ranging from 4 to 14 %). 
Gannet combined with LCModel approach proved the best method. (CV = 4 – 5 %). 
Measurements from the ACC region had higher CVs than the inferior frontal gyrus 
(Broca’s region). (CV = 6 – 14 % vs 4 – 7 %), indicating that measurements from 
Broca’s region are more reproducible.  
PAPER III: The GSH “Christmas phantom” study 
Both MEGA-PRESS and PRESS showed degradation of the measured GSH signal.  
The modelled curves gave for t = 0, GSH = 2.9 institutional units (i.u.) for MEGA-
PRESS and GSH = 2.3 i.u. for PRESS (start concentration of GSH was 3.0 mM). T 
® ∞ gave ~ 0 i.u. for MEGA-PRESS and 0.7 i.u. for PRESS. After ~1 year, the 
concentration of GSH in the phantom measured by MEGA-PRESS was 0 i.u. and for 
PRESS 0.6 i.u. Assuming that PRESS also includes GSSG in its GSH fit, the 
theoretical PRESS measured GSH value from the 1 year follow-up phantom was 
calculated to be 0.7 mM. 
PAPER IV: GSH edited MEGA-PRESS reproducibility 
Between-session variability of GSH edited MEGA-PRESS stabilised at around 128 
paired repetitions (~8 min, CV ~ 11 – 12 %). Between-session CV-values for the 
PRESS sequence were 20 – 26 % and for STEAM 16 – 20 %. CV values for within-
session variability of MEGA-PRESS edited GSH measurements dropped to ~ 4 % at 
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128-144 paired repetitions There were no correlations between GSH values measured 
with MEGA-PRESS, STEAM and PRESS, and no differences in measured GSH 




To simplify terms for the discussion; the GABA edited MEGA-PRESS in ASD study 
will be referred to as the ASD study and the GABA edited MEGA-PRESS 
reproducibility study and the GSH edited MEGA-PRESS reproducibility study will 
be referred to as the GABA reprod and GSH reprod study, respectively (or just the 
reprod studies where both studies are involved) in the discussion section.  
The discussion section is divided into methodological considerations and discussion 
of the results. In methodological considerations, the data collection in the four studies 
are discussed with emphasis on inclusion/exclusion criteria, voxel size and 
placements. The reason for the somewhat illogical study order (first ASD study, then 
the reprod studies) is also explained. A special section is dedicated to the discussion 
of the MRS method in general, and the MEGA-PRESS in particular. What is actually 
measured in GABA edited MEGA-PRESS is also addressed. As the subtitle implies, 
in discussion of the results, the results of the four studies are discussed. 
5.1. Methodological Considerations  
5.1.1. Data collection: The ASD study  
Inclusion/exclusion criteria 
The ASD diagnosis displays a significant clinical heterogeneity, and defining 
inclusion and exclusion criteria when planning an ASD study is challenging. The 
researcher wants to study the core elements of ASD, not its comorbidities, but 
perhaps the comorbidities are an integrated part of the ASD symptom complex? The 
inclusion/exclusion criteria in the ASD study were comparable to similar studies, 
with two exceptions. Firstly; females are not included in the study. There are 4-5 
times as many boys as girls with the diagnosis (53), and the clinical presentation of 
the disorder is different in females than males (116). Girls have social and personal 
attributes that masks or compensate for ASD symptoms to a greater extent than what 
boys have. Biological factors may protect girls from the condition to develop in the 
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first place (117). In order to make the ASD group as homogenous as possible and 
avoid statistical power issues by including girls, it was decided to only study boys. 
Secondly, epilepsy was not an exclusion criterion in our study. ASD and epilepsy are 
conditions that are highly connected, and by excluding children with epilepsy, the 
ASD group would not be representative of children with ASD in general.  
14 of 20 boys in the ASD group managed to carry out the MR examination with 
acceptable MRS data. The MRS data of these 14 boys were of same quality as the 
MRS data of the included TD boys. There definitely exists a selection bias in whom 
of the boys managed to perform the MR examination, and who did not. For example, 
boys with ASD extremely sensitive to loud noises had greater difficulties in 
completing the MR examination. A success rate of 14/20 also makes it questionable 
whether MRS is truly a feasible investigation tool for future clinical application in 
this group.  
The VOI 
Setting up MRS experiments is also challenging when it comes to choosing which 
region of the brain one wants to examine. The MEGA-PRESS technique for both 
GABA and GSH editing is not yet available as multi-voxel spectroscopy, and the 
chosen VOI needs to be rather large in order to acquire enough data to get acceptable 
SNR. As confirmed in the GABA reprod study, GABA edited MEGA-PRESS from 
one VOI takes ~12 min. This greatly limits how many brain regions that can be 
examined in one experiment.  
The left ACC region was chosen as VOI in the ASD study for its involvement in 
higher cognitive and intellectual functioning. The frontal lobe is one of the more 
difficult regions in the brain to acquire MRS data from, mostly due to problems with 
air from the paranasal sinuses. The GABA reproducibility study did however show 
that reliable GABA measurements can be achieved in this area.  
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5.1.2. Data collection: The reprod studies 
Inclusion/exclusion criteria 
Inclusion and exclusion criteria in the GABA and GSH reprod study were more 
straight forward. Females were not included in the GABA reprod study. There are 
mixed results in the literature whether gender affects GABA levels (118, 119) and it 
was therefore decided, for a pure reproducibility purpose, to only study males. In the 
GSH reprod study, however, females were included. As far as we are aware of, there 
is only one previous study examining gender differences in GSH edited MEGA-
PRESS (120). With twice the sample size as the GABA reprod study, the GSH reprod 
study became then not only a reproducibility study, but also a study where potential 
gender differences could be examined.  
The VOI 
Even though there is good reason to assume a degree of transferability of results 
between the GABA or GSH reprod studies from one ROI to another, the results from 
the reproducibility studies will most likely only apply for the regions examined. The 
ACC and auditory cortex regions are of particular interest for the extended research 
group (fMRI group), and were therefore chosen. In the GSH reprod study, a voxel 
placement in the occipital lobe was also included. This is a brain region where 
achieved MEGA-PRESS quality is known to be good, and the region has also 
previously been used in GABA edited MEGA-PRESS reproducibility studies (121, 
122).   
With regard to voxel size, a 27 ml voxel was applied in the ASD study while voxels 
of ~ 21 ml are applied in the reprod studies. A voxel size of 27 ml for GABA edited 
MEGA-PRESS have been previously considered best practice (22), however a 
somewhat smaller voxel gives adequate signal and is also easier to position in the 
brain. In addition, a smaller voxel gives less partial volume effects.  
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5.1.3. MRS limitations 
One of the main limitations of MRS is the need for large voxel sizes resulting in poor 
spatial resolution. Because in vivo metabolites are in the mM concentration range, 
voxel sizes must be sufficiently large to obtain enough signal to generate a high-
quality spectrum. As mentioned earlier, multi-voxel spectroscopy is not yet available 
for GABA and GSH edited MEGA-PRESS, and it is too time consuming to cover the 
entire brain with single voxels. The achievable spatial coverage is in other words also 
poor. 
It is crucial that the participant lie still in the scanner since head movements shift the 
region where MRS is obtained. This may be to regions of no interest, or to a region 
that contains fat, CSF or air, which will ruin the MRS spectra. It is even more 
important that the participant lie still when performing MEGA-PRESS than regular 
PRESS for several reasons: 
• The scan times for MEGA-PRESS acquisitions are longer.  
• It is the difference spectra that are used for quantification. 
• The preciseness of the editing pulse is affected due to motion related 
frequency changes.   
Another limitation is the chemical shift displacement error (CSDE) which describes 
the inaccuracy of the slice localization. CSDE is proportional to B0 and inverse 
proportional to the bandwidth (BW) of the RF pulse excitation. PRESS and STEAM 
are localization sequences with narrow BW while the newer SVSs LASER and semi-
LASER acquire a localization method (adiabatic) with wider BW.    
In addition to more accurate volume selection, and by this avoiding CSDE, adiabatic 
pulses compensate effectively for B1 inhomogeneity and can provide more SNR at 
high magnetic fields. Following this, GABA and GSH edited MEGA –LASER is 
thought to replace MEGA-PRESS in the future.  
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5.1.4. GABA+: What are we actually measuring? 
The spectral editing techniques applied in our studies does not separate the GABA 
signal from MM. A considerable MM component is also affected by the editing pulse 
which means that the resultant GABA+ measurements includes of as much as ~60% 
MM. There are several different approaches to overcome the unwanted MM 
coediting, the most popular being placing symmetrical editing pulses about the MM 
resonance at 1.7 ppm (ON/OFF 1.9/1.5 ppm) (123). However, the reproducibility of 
the MM-suppressed GABA edited acquisition is poorer than the standard GABA-
edited acquisition since MM-suppressed GABA measurements seem more 
susceptible to B0 field changes resulting from scanner drift and participant head 
motion (124).  
Another concern in interpretation of GABA measurements from spectral editing 
techniques is what the measurements actually represent. There are three pools of 
GABA in the CNS, all with different roles, and some of the GABA pools may be 
more tightly bound (less “visible” for GABA edited MEGA-PRESS) than others 
(125). 
- Cytoplasmic GABA exists throughout the neurons. The 67kD enzyme glutamic 
acid decarboxylase (GAD) that catalyses the decarboxylation of Glu 
to GABA and CO2 is tonically active and this GABA pool is believed to have a 
role in the cells metabolism.  
- Vesicular GABA exists in the vesicles in the axon terminals. The 65kD GAD 
enzyme which catalyses the formation of GABA here is phasically active, and 
this GABA pool plays a role in inhibitory synaptic neurotransmission.  
- Free extracellular GABA acting on extra synaptic GABA receptors. The third 
GABA pool is less studied that the two others, nevertheless, this pool appears 
to have a tonic, neuromodulatory role in cortical inhibition. 
The ratio of vesicular to cytosolic GABA has not been directly measured. It is most 
likely dynamic and highly dependent on cellular activity and the availability of 
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precursors (126). All this implies that measured GABA concentration cannot simply 
be regarded as the same as neurotransmitter GABA. Changes in metabolism and even 
modulation of blood flow must be taken into consideration when interpreting the 
GABA measurements. 
However, several studies have demonstrated the relationship between behaviour and 
spectral edited GABA measurements (127-129), which means that the GABA 
measurements at least correlates in one way or another with the neurotransmitter and 
neuromodulator pools of GABA in the cortex.  
5.1.5. The order of the studies 
An important methodological limitation of the thesis is that the GABA edited 
MEGA-PRESS reproducibility study came after the GABA edited MEGA-PRESS 
had been applied in the ASD study. The acquisition parameters in the MR protocol 
were different in the two reprod studies and in the ASD study. The ASD sample were 
boys aged 6-13 years, while the reprod studies sample were young healthy men aged 
18-35 years. GABA edited MEGA-PRESS was set up on our MR machine just before 
the start-up of the ASD study. A GABA reprod study on healthy male adults, but with 
the same acquisition parameters as the ASD was performed, but the quality of the 
spectra from this study was markedly poorer than the ASD study. Another GABA 
edited MEGA-PRESS reproducibility study was performed, but again – the data 
quality was poor. A scanner upgrade followed with the installation of a new magnet 
and updated software - a “forklift upgrade”. Testing the reproducibility of a study 
done before the scanner upgrade had no meaning, and it was therefore decided to 
design the next reproducibility study to match GABA edited MEGA-PRESS 
appliances in future studies.  Updated acquisition parameters were therefore used in 
the GABA edited MEGA-PRESS reproducibility study, which was then basically the 
third reprod study.  
Both the quality of the acquired MRS spectra and the quality of the fit of the MRS 
spectra in the ASD study were checked as described in earlier sections. It would, 
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however have been preferable to have done a reproducibility study before the ASD 
study in order to assure the quality of the method properly. This is one of the main 
lessons learned in this thesis; not to include a novel MR sequence in study protocols 
without having tested it thoroughly on beforehand. Nonetheless, our group would 
probably not be this advanced in the MRS editing techniques if the GABA edited 
MEGA-PRESS sequence had not been included in the ASD study. 
5.2. Discussion of Results 
5.2.1. The ASD Study 
There were no statistically significant differences between the two groups (ASD/TD) 
in GABA+ and GABA+/tCr levels.  
A few studies have shown a reduction in the GABA concentration in individuals with 
ASD, compared to healthy controls, at a couple of different voxel placements in the 
brain. There are reasons to believe that these differences, given that they exist, are not 
present globally throughout the brain. Two studies have shown reduced GABA/tCr 
concentration in the ASD group compared to healthy controls in the right 
sensorimotor cortex, but no significant differences were found in the middle occipital 
cortex. One study showed significant reduced GABA/tCr concentration in the ASD 
group compared to healthy controls in the left motor cortex and the left auditory, but 
no significant differences were found in the left auditory cortex. One final study – the 
Harada study- found no differences in GABA/tCr concentration in the lenticular 
nuclei, but they did find lower GABA/tCr in the ASD group compared to healthy 
controls in the left frontal lobe. The frontal voxel position in their study is 
comparable to the voxel position applied in our ASD study. However, as pointed out 
in the Paper I, there were several concerns which may question the results in the 
HARADA study: Most of the children were sedated with triclofos sodium (a GABA 
agonist), the subjects had a wide age range, and there was no information whether the 
included subjects were boys or girls. We do not know how these factors affects MRS 
measured GABA concentration. 
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The ROIs described in the previous section are the only regions in the brain where 
these types of GABA measurements have been performed in children with ASD. The 
numbers of participants with ASD with measurements from each ROIs are also fairly 
low ranging from a total of 8 (auditory cortex (82)) to 48 (sensorimotor cortex (82, 
84)). 
GABA levels fluctuate and are dependent on cell metabolism, neuronal activity and 
blood flow. There is a need to replicate previous findings in larger participant-groups 
with a more optimized MRS sequence.  
The GABA measurements described in the previous studies are snapshot-
measurements from a relatively large brain region, and it is therefore difficult to 
interpret if there is any functional relevance of these changes. Using MRS to show 
functionally specific correlations between GABA levels and behaviour in individuals 
with ASD may prove valuable for future studies in the area. For example, Puts et al 
2016 (84), found associations between GABA levels in children with ASD and tactile 
behavioural abnormalities present in this group. 
All MRS studies on children and adults with ASD suffer from selection bias; only 
high- functioning individuals with ASD will be able to complete a MR examination 
with acceptable quality of MRS spectra. It is a reasonable assumption that an 
eventual difference in measured GABA levels would be larger between more affected 
ASDs (more severe ASD symptoms) and healthy controls. ASSQ is a screening 
questionnaire applied worldwide for registering ASD symptom severity. A high score 
means more ASD symptoms, and a score below 17 makes the ASD diagnosis rather 
unlikely (130). In the ASD study we did find a negative correlation between 
measured GABA levels and ASSQ score. The higher the ASSQ score the lower 
GABA levels. The findings nicely agree with the E/I theory in ASD. 
However, one should take caution when interpreting correlations, since correlations 
do not allow for causality. Although it was statistically significant, the correlation did 




An interesting question when looking at the results in the ASD study is, for whom 
does these results apply? Are they transferable to a female ASD population or other 
age groups? A safe answer would be that they apply to high-functioning boys. 
5.2.2. The Reprod Studies & the “Christmas phantom” study 
5.2.2.1. Optimal number of repetitions 
The optimal number of repetitions for GABA edited MEGA-PRESS derived from the 
GABA reprod paper is 220 paired repetitions, however a CV of under 8 was achieved 
for both the ACC and the Broca region at around 160 paired repetitions. When 
looking at the early work on GABA edited MEGA-PRESS, 128 paired repetitions 
was the standard (8, 131) and this was also the number of paired repetitions applied 
in the ASD study. The paper by Mullins et al (22) did not discuss the effect of scan 
length, and did not contain any recommendations on how many repetitions that is 
ideal. A previous study from our group (122) found, in line with the GABA reprod 
results, that the optimal scan length was 256 paired repetitions (with TR 1500 msec 
gives TA~13 min)  in a 27 ml voxel placed in the occipital lobe. The most recent 
studies measuring GABA with MEGA-PRESS uses between 256-288 (132, 133) 
paired repetitions. 
220 paired repetitions give a scan length of roughly 13 min depending on TR time, 
which can be challenging for patients. However, GABA edited MEGA-PRESS with 
this scan length have been applied in several group studies with different patient 
groups such as schizophrenia (134), depression (9), ADHD (135), ALS (18), diabetic 
neuropathy (19) and neurofibromatosis.  
The optimal number of repetitions for GSH edited MEGA-PRESS were found to 128 
paired repetitions (TA ~ 8 min), in other words much shorter that for the GABA 
edited MEGA-PRESS. However, the CV never was never lower than 10. This may 
imply that there might be more work to do to optimize the GSH edited MEGA-
PRESS technique, or that GSH levels fluctuate more than GABA levels.  
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Averaging GABA/GSH quantification results over a group is one thing, using the 
quantification results from one single individual is another thing. On a single subject 
basis, the MRS measured signals from GABA and GSH signals are too low and 
disease unspecific, and the intra-and interindividual variations are too high. These 
sequences are therefore only suitable for group comparisons and not for diagnostic 
purposes at the moment. 
5.2.2.2. Comparing GSH edited MEGA-PRESS with PRESS and 
STEAM 
Between-session CVs from the GSH reprod study revealed that PRESS and STEAM 
had far worse reproducibility in both brain regions measured (20 – 26 % for PRESS 
and 16 – 20 % for STEAM). There were no correlations between GSH levels 
measured with MEGA-PRESS, PRESS or STEAM, implying that the three methods 
might actually not be measuring the same thing. 
It is important at this point to acknowledge the differences in the two measuring 
techniques. Where MEGA-PRESS is directly measuring a distinct peak through the 
editing approach, PRESS and STEAM relies on a model assumption of 
concentrations (prior information). It is actually not possible to visually inspect the 
GSH signal in the PRESS (and STEAM) spectra.  
The results from the decaying GSH measurements by MEGA-PRESS and PRESS in 
the “Christmas phantom” study showed that the GSH PRESS fit also included the 
product of oxidation – GSSG. What guarantees do we have that the PRESS 
measurement, or STEAM for that matter, are not including other metabolites with 
similar resonance frequencies the in vivo fitted result of GSH. 
A concern with GSH edited MEGA-PRESS is the relative long TE (131 msec) 
required to achieve an optimal editing efficiency. This combined with the rather short 
T2 of GSH (T2 = 67 msec at 4T (136)) gives rise to considerable signal loss 
compared to short-TE PRESS. This is also evident from the GSH reprod study where 
69 
 
SNR from MEGA-PRESS measurements from the middle OCC and left ACC were 
34.3 and 16.1 while SNR from PRESS were 56.1 and 38.2 respectively. This is a 
trade-off that has to be acknowledged. However, what use is it to apply a sequence 
with higher SNR if we are not certain that it is only measuring the signal from the 







The ASD Study:  
The aim of the ASD study was to explore the E/I hypothesis in children with ASD 
using both the PRESS and MEGA-PRESS sequence. A negative correlation was 
found between autism severity, as measured by the ASSQ, and GABA in the ASD 
group. However, no group level differences in GABA was found between the ASD 
and TD group. The ASD study underlines that the severity of autism symptoms has to 
be taken into account when examining the E/I hypothesis in ASD.  
The GABA reprod study: 
The aim of the GABA reprod study was to examine the within-and between-session 
reproducibility of the MEGA-PRESS sequence, focusing on optimizing the scan 
lengths in vivo. Reliable GABA measurements can be achieved in the frontal lobe 
when using appropriate scan parameters and corresponding experimental design.  
The GSH “Christmas phantom” study:  
The aim of the “Christmas phantom” study was to examine how well GSH edited 
MEGA-PRESS and PRESS was able to measure the degradation of GSH in a 
phantom. Both methods managed to measure the degradation, but the modelled 
degradation curve for the MEGA-PRESS data was more accurate. 
The GSH reprod study:  
The aim of the GSH reprod was to examine the GSH measured reproducibility of the 
MEGA-PRESS, STEAM and PRESS sequence in vivo. In addition, gender 
differences were examined. Reliable GSH measurements were found for MEGA-
PRESS. No significant correlations were found in measured GSH levels between the 




The work in this thesis has expanded the foundation of the MEGA-PRESS sequence, 
bringing it one step further towards increased reproducibility and reliability of 
measured GABA and GSH levels. The GABA and GSH reprod study gives good 
evidence of which number of repetitions that should be selected when designing new 
GABA or GSH edited MEGA-PRESS studies. Another result that may be of 
importance when designing GSH reproducibility studies is that there seems be no 
differences in measured GSH levels in males and females, even when the use of 
hormonal contraceptives is taken into account. Lastly, results from the “Christmas 
phantom” study and the GSH reprod study supports the argument that short TE single 
voxel sequences STEAM and PRESS are not accurate enough to measure GSH in 
vitro and in vivo. The more advances sequences, such as the MEGA-PRESS, are 
needed.  
With the existing MRS sequences, more work needs to be done when it comes to 
which brain regions that are examined. More work also needs to be done examining 
the effects age and gender may have on the measured metabolite levels. The newer 
more advanced HERMES and PRIAM sequences with multi editing and dual voxel 
acquisitions, which might be the future of edited MRS techniques, needs to undergo 
the same level of validation before they are applied in research.   
The local effort with MEGA-PRESS in Bergen has contributed to a broad 
collaboration between several leading MRS groups worldwide. This includes the 
involvement in a multi-site project (the Big GABA project (124) with an agenda to 
validate, push forward and further develop MRS measurements of GABA using the 
MEGA-PRESS sequence. The international collaboration will continue in the future, 
including editing of more metabolites.  
MRS is still by some considered an “investigational technique” and “the forever just 
promising technique” 30 years after the first promising papers on MRS in acute 
stroke, multiple sclerosis and brain tumours were published. Though some clinicians 
are desperate if MRS spectra are not acquired as a part of the standard MRI tumour 
investigation, others could not care less. The question is: Will the newer more 
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advanced MRS techniques, such as edited MEGA-PRESS, revolutionize MRS and 
forever convince the doubters that MRS has an important role in the field of 
neuroradiology? Probably not, or at least not for GABA and GSH edited MEGA-
PRESS. 2HG and Lac edited MEGA-PRESS, on the other hand, might be of 
considerable value in clinical MRI brain protocols in the future.  
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7. FUTURE PERSPECTIVES 
As mentioned in chapter 1, in vivo measurement of GABA and GSH is currently an 
area of great interest in modern neuroimaging, and with this a constant stream of 
methodological development of MRS has evolved. A tighter collaboration between 
the leading MRS cites in the world, as initiated by for example the Big GABA 
project, will make it easier to compare data between different studies across different 
research cites and vendors. 
At present, dual editing and dual voxel excitation is the state of the art in MRS. The 
possibility of measuring GABA and GSH simultaneously is a promising development 
in the MRS field. Both metabolites are of great interest in a wide range of 
neuropsychiatric disorders, neurodevelopmental disorders and neurological disorders. 
It is an enchanting prospect for many researchers to get both metabolites (at two 
voxel placement) at the same time. This is, however, probably just the beginning. 
Multi-editing techniques are currently under development with an ultimate goal of 
whole brain coverage with CSI type techniques. 
Another bonus in improving the MEGA-PRESS editing sequence and building 
international consensus for standardized study design and acquisition protocols for 
MEGA-PRESS parameters, is the transferability to other metabolites that can be 
edited. The most interesting metabolites in a clinical aspect is Lac and 2HG.  
Elevated Lac indicates anaerobic glycolysis, and the appearance of an obvious Lac 
peak strongly suggests a pathological process such as ischemia, tumour, trauma, 
infection or mitochondrial disease. Small increases in Lac may reflect subclinical 
inflammation, impairment of oxidative metabolism, or increased neural activity 
(137). The Lac doublet at 1.33 ppm is usually significantly overlapped by MM and 
lipids. To overcome this, longer TEs (TE 144 msec and TE 188 msec) are often used 
in clinical settings. A problem with this is that the signals are lost with longer TE, 
something which may lead to false negative results. 
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In Lac edited MEGA-PRESS, the editing pulse is applied to the methane spin at 
4.1 ppm and the signal is measured from the methyl spin at 1.32 ppm. TE is also long 
(140 msec), but since all the overlapping signals are removed, enough signal still 
remains for quantification. 
2HG is a tumour biomarker, and is present at very low levels in healthy brain tissue.  
It may be present in the mM range in tumours with a isocitrate dehydrogenase 
mutation (grade 2 and grade 3 gliomas in adults.) Interestingly – the editing pulse is 
applied at the 1.9 ppm peak – same as with GABA editing. The 2HG peak measured 
is the 4.01 ppm peak. 
Individuals that are diagnosed with ASD are, even if they share the same diagnosis, 
affected very differently. In what way do researchers expect that the GABA edited 
MEGA-PRESS, or similar sequences, can help to, first of all; diagnosing ASD, and 
second of all; understanding the variations of the diagnosis, and why there seem to be 
a difference in how it often expresses itself differently in men versus females? The 
most optimistic amongst ASD researchers believe that these sequences will have an 
important role in the future in the diagnosis of ASD and other neurodevelopmental 
and psychiatric diseases. The more pessimistic researcher would argue that the 
method at most can be applied in research settings only – and have no use in clinical 
settings. In the middle, there is a more moderate view which claims that GABA-
edited MEGA-PRESS measurements may become a biomarker to identify which 
ASD subjects that might have effect of treatment with for example GABA analogue 
drugs like gabapentin and monitoring treatment. The GABA edited MEGA-PRESS 
method has been known for more than 20 years. There has, however, not been 
performed enough studies using GABA edited MEGA-PRESS´ appliance and utilities 
in ASD, to assert the role of this method. There is a severe lack of studies with both 
males and females with ASD, at different ages, and with different symptoms. Such 
studies, where also multiple brain regions are examined, need to be conducted in 
order to see if there are any common denominators. 
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As of today, Haukeland University Hospital is the only Hospital in Norway using the 
MEGA-PRESS sequence. Expanded use of the MEGA-PRESS sequence and similar 
advanced MRS techniques at more research cites might just be what is needed in 
further developing the understanding of diseases like ASD. Without learning more 
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Magnetic resonance spectroscopy (MRS) from voxels placed in the left anterior cingulate
cortex (ACC) was measured from 14 boys with Autism Spectrum Disorder (ASD) and 24
gender and age-matched typically developing (TD) control group. Our main aims were
to compare the concentration of γ-aminobutyric acid (GABA) between the two groups,
and to investigate the relationship between brain metabolites and autism symptom
severity in the ASD group. We did find a significant negative correlation in the ASD group
between Autism Spectrum Screening Questionnaire (ASSQ) and GABA+/Cr, which may
imply that severity of symptoms in ASD is associated with differences in the level of
GABA in the brain, supporting the excitatory/inhibitory (E/I) imbalance theory. However
we did not find a significant difference between the two groups in GABA levels.
Keywords: ASD, GABA, MRS, MEGA-PRESS, ASSQ
Introduction
Autism Spectrum Disorder (ASD) is a pervasive developmental disorder characterized
by deficits in social communication and social interaction and by restricted, repetitive
patterns of behavior, interests or activities. Symptoms must be present in an early
developmental period (before 3 years of age), but they do not necessarily become
Abbreviations: ASD, Autism Spectrum Disorder; MRS, Magnetic Resonance Spectroscopy; ppm, Parts per million;
NAA, N-acetylaspartate; Glu, Glutamate; Gln, Glutamine; MI, Myo-inositol; Cho, Choline; Cr, Creatine; PCr,
Phosphocreatine; GABA, Gamma-aminobutyric acid; MM, Macromolecules; GABA+, GABA including associated
MM; E/I, Excitatory/inhibitory; TD, Typically developing; SIB, Unaffected siblings; Glx, Glutamate and glutamine;
ACC,Anterior cingulate cortex; ASSQ,Autism SpectrumScreeningQuestionnaire;WASI,Wechsler Abbreviated Scale
of Intelligence; DAWBA, Development and Well-Being Assessment; SDQ, Strengths and Difficulties Questionnaire;
ADHD, Attention deficit/hyperactivity disorder; ADD, Oppositional defiant disorder; TR, Repetition time; TE, Echo
time; CRLB, Cramér-Rao lower bounds; CSF, Cerebro spinalfluid; Gray, Gray matter; White, White matter.
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fully manifest until social demands exceed limited capacities
(American Psychiatric Association, 2013). The estimated
prevalence of ASD in the Norwegian population ranges
from 0.44 to 0.87% (Heiervang et al., 2007; Posserud
et al., 2010; Surén et al., 2012) with four times as many
boys as girls diagnosed with the disorder (Baron-Cohen
et al., 2009b). Autism is now called ‘‘spectrum disorder’’
because of the recognition that its manifestation and severity
displays great heterogeneity depending on intellectual ability,
associated symptoms, possible etiology and developmental
level (American Psychiatric Association, 2013). Although
there is clearly a genetic basis to ASD, the majority of cases
have unknown causes (Abrahams and Geschwind, 2008;
Geschwind, 2008). It is, moreover, now widely accepted that
ASD is a neurobiological disorder, but specific biological
markers are yet to be established (McPheeters et al., 2011;
Warren et al., 2011).
Magnetic resonance spectroscopy (MRS) has made it possible
to study the concentration of biochemical substances in the
healthy and diseased brain (Soares and Law, 2009). By measuring
from a volume element (MRS voxel) in specific regions of
interest, metabolite concentrations can be estimated due to
differences in spectral resonances from the main water peak.
Using the PRESS (Point RESolved Spectroscopy) single-voxel
spectroscopy sequence (Bottomley, 1987), metabolites such as
N-acetylaspartate (NAA), glutamate (Glu), glutamine (Gln),
myo-inositol (MI), choline (Cho) and creatine (Cr), can be
measured. Unfortunately, other important metabolites such
as γ-aminobutyric acid (GABA) are not detectable using
conventional MRS, due to spectral overlap with more abundant
metabolites at 3.02 parts per million (ppm). One way to
measure the concentration of GABA is with a spectral editing
technique such as BASING (Star-Lack et al., 1997) or MEGA-
PRESS (Mescher et al., 1998). A pair of frequency selective
inversion pulses within a standard PRESS sequence allows
discrimination between overlapping coupled and uncoupled
spins. For GABA editing the editing pulses are applied to
the C-3 protons of GABA at 1.9 ppm. Due to the spin-
spin coupling the C-4 protons of GABA at 3.02 ppm are
affected while other metabolite peaks like the strong Cr
peak remains unaffected. Subtracting the spectrum from a
second acquisition scheme without these editing pulses (or
applied symmetric to the water signal, e.g., at 7.5 ppm),
will give a difference spectrum without the strong singlet
signal from Cr, allowing quantification of the GABA peak
at 3.02 ppm. As these GABA protons are also coupled
to macromolecules (MM) at 1.7 ppm this peak consists
of GABA and an unknown contribution of MM signal
and is therefore named GABA+ (GABA+ MM). This is
in line with current best practices (Mullins et al., 2014)
and hence compatible with the bulk of existing research
including studies on ASD (Gaetz et al., 2014; Rojas et al.,
2014).
Glutamate is the major excitatory neurotransmitter and
GABA is the major inhibitory neurotransmitter in the brain,
and probably all areas receive input from both of these
neurotransmitters. The balanced interaction between excitatory
and inhibitory neurotransmission is tightly regulated (Carlson,
2001) and is essential for controlling cognition, learning,
memory and emotional behaviors. Several studies support
the idea that imbalance in the glutamate/GABAergic system
could be present in a wide range of disorders with quite
different clinical appearances, like Downs syndrome, epilepsy,
neurofibromatosis and schizophrenia (Ramamoorthi and Lin,
2011).
Lately increasing evidence have emerged suggesting that also
ASD may be associated with abnormalities in the glutamate
and GABA system including neurotransmitters, receptors and
enzymes (Pizzarelli and Cherubini, 2011) often referred to as
the excitatory/inhibitory (E/I) imbalance theory. It has been
hypothesized that the E/I ratio in the cortex is unusually high,
either due to increased glutamate—or because of decreased
GABAergic signaling (Rubenstein and Merzenich, 2003). An
E/I imbalance might explain the typical ASD symptom of
hypersensitivity to sensory stimuli, including aversion to loud
noises, tactile stimulation, and bright lights (Kanner, 1943;
Baron-Cohen et al., 2009a).
GABAergic dysfunction in ASD has been proposed in animal
models (Gogolla et al., 2009; Chao et al., 2010), post mortem
studies and in vivo human studies; see overview Coghlan et al.
(2012). The E/I imbalance hypothesis is also consistent with
the observation that rates of epilepsy are higher in the autism
population than in the general population (Gillberg and Billstedt,
2000). Another important finding is that gamma oscillations
are reduced in ASD patients (Grice et al., 2001; Brown et al.,
2005; Wilson et al., 2007). Gamma oscillations a re generated
by GABAergic neurons (Pizzarelli and Cherubini, 2011), and
are involved in sensory binding and higher cognitive functions
(Lisman and Idiart, 1995).
When starting this study, there was, to our knowledge, only
one previous study using theMEGA-PRESS sequence to measure
the concentration of GABA in the brain of children with ASD
compared with normal controls, and our study was designed to
further explore the E/I theory. Harada et al. (2011b) reported
significantly lower GABA+/NAA and GABA+/Glu ratio in a
voxel placed in the left frontal lobe in a population of children
with ASD aged 2–11 years compared to a typically developing
(TD) control group (n = ASD/TD: 12/10). Since then two
more studies have been published. Gaetz et al. (2014) had three
different spatially localized voxels; in the left motor cortex (n =
17/15), left auditory cortex (n = 15/11) and the left visual cortex
(n = 8/10), respectively. They found that the GABA/Cr ratio
was significantly reduced in the motor and auditory cortex, but
not significantly different in the visual areas in ASD children
aged 11.5 ± 2.7 years compared to TD. The last study, Rojas
et al. (2014), found reduced GABA/Cr ratio in a voxel placed
in the left auditory cortex in children with ASD aged 14 ±
5 years compared with their unaffected siblings (SIB) aged
12 ± 6 years, and TD aged 12 ± 5 years (n = ASD/SIB/TD:
17/14/17).
To explore the excitatory/inhibitory imbalance theory
our aim was to study children aged 6–13 with ASD without
sedation using both PRESS and MEGA-PRESS sequence.
Since studies in healthy individuals have shown significantly
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higher concentrations of GABA, Glutamate + Glutamine
(Glx), and Glu in males compared to females (O’Gorman
et al., 2011), only boys were included in the current
study.
MRS measured metabolite concentrations are normally
presented as ratios of water, total Cr, NAA or in the case of
GABA, Glx have also been used. The concentrations obtained
from MEGA-PRESS use water as an internal concentration
reference, meaning that all our GABA+ data are scaled to water.
We have chosen to display our results as GABA+ and GABA+/
Cr since there are reports from previous studies that there exist
group differences between ASD and TD in both NAA (Aoki
et al., 2012) and Glx (Horder et al., 2013). Gaetz et al. (2014)
and Rojas et al. (2014) also used GABA+/Cr to present their
results.
We assessed GABA and other brain metabolite levels from a
voxel in the left anterior cingulate cortex (ACC) using a voxel size
of 30 × 30 × 30 mm3 (27 ml) see Figure 1.
Although closer to the midline of the brain, this voxel
placement partly overlaps the voxel placement in the Harada
et al. (2011b) study. This was one of the few locations in the
frontal lobe where it was possible to fit the relatively large voxel
without including bone or cerebrospinal fluid (CSF) in these
children. The dorsal portion of the ACC has been shown to be
involved in higher cognition and intellectual functioning (Bush
et al., 2000), and other studies have in particular implicated the
left ACC in patients with mental disorders (Minzenberg et al.,
2009).
All participants were assessed using the Autism Spectrum
Screening Questionnaire (ASSQ) and parts of the Wechsler
Abbreviated Scale of Intelligence (WASI) as variations
in both autism severity and intellectual level may have
an impact on metabolite levels. To explore the possible
relationship between autism severity and GABA, our GABA+
measurements were correlated with the ASSQ scores (Ehlers
et al., 1999). In accordance with the E/I imbalance hypothesis,
we hypothesized that we would find a lower concentration of
GABA+ and GABA+/Cr ratio in the ASD group compared
with the TD group, and that the GABA+ concentration and




The boys in the ASD group were recruited through parents
groups, patient organizations, newspaper advertisements, from
the educational and psychological counseling service in the
municipality, and from patients receiving care at a private
clinic. The boys in the TD group were recruited from the
National Registry. The boys in the ASD group had been
independently assessed and diagnosed by child psychiatric
outpatient clinical specialists in Norway. Documentation of
the clinical assessment leading to an ASD diagnosis was
requested and reviewed by a clinical ASD expert (co-author
M.P.) for all ASD boys to confirm the ASD diagnosis and
ensure that they fulfilled the diagnosis also according to the
DSM-5 criteria (American Psychiatric Association, 2013). In
addition the parents/legal representatives in the TD group
were interviewed using the ASD section of the structured
interview Development and Well- Being Assessment (DAWBA)
to exclude presence of ASD in the TD group (Goodman
et al., 2000). Height and weight of all participants were
measured prior to imaging and the parents filled out a screening
questionnaire for mental health including the Strengths and
Difficulties Questionnaire (SDQ; Goodman, 1997), the ASSQ
(Ehlers et al., 1999), items on learning problems, obsessive
compulsive disorders, tics and the DSM-IV criteria for attention
deficit/hyperactivity disorder (ADHD) and oppositional defiant
disorder (ODD), to rule out presence of neuropsychiatric
conditions in TD children (Heiervang et al., 2007; Posserud
et al., 2009). The ASSQ has been thoroughly validated as
measure of ASD and was furthermore used as measure of
autism severity (Ehlers et al., 1999; Posserud et al., 2009).
FIGURE 1 | Placement of magnetic resonance spectroscopy (MRS) voxel in the left anterior cingulate cortex (ACC). This figure shows the typical
placement of the 3 × 3 × 3 cm MRS voxel in the left ACC.
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The two sub-tests Vocabulary and Matrices Reasoning of the
WASI as tests of general intellectual capacity and cognitive
skills (Wechsler, 1999) were assessed in both groups by
trained psychology students. In addition, information regarding
ethnicity, other illnesses, medication, and supplements and
diets were noted. Exclusion criteria in both groups were
braces (for the MR investigation), genetic abnormalities and
prematurity (<36 weeks). Epilepsy, autistic traits and other
neuropsychiatric disorders were exclusion criteria in the TD
group.
We included boys with epilepsy in our ASD group since it
is estimated that 30% of ASD patients also have epilepsy, and
subclinical epileptiform activity is recorded on scalp EEG in
up to 85% of children with ASD (Gillberg and Billstedt, 2000;
Yasuhara, 2010). By excluding children with epilepsy we found
that our ASD group would not be representative of children with
ASD in general.
In the ASD group, 20 boys were initially recruited from which
14 (mean age 10.2 ± 1.9 years), completed the MRI examination
with acceptable PRESS andMEGA-PRESS data as per our quality
criteria described in the later ‘‘MRS data analysis’’ section. Three
boys in the ASD group did not complete the WASI tests but they
were nevertheless included for MRS analyses.
TD boys were recruited as control participants. In the TD
group, 30 boys were initially recruited. Three of them were
excluded prior to the data analyses; one had a large arachnoid
cyst, and two scored above the 90-percentile relative to the
population norm from the Bergen Child Study (Heiervang et al.,
2007) on the screening questionnaires. Three TD boys did not
complete the MR examination. This resulted in a total of 24 boys,
mean age 10.2± 1.8 years in the TD groupwith acceptable PRESS
data, while MEGA-PRESS data was acceptable in 21.
Ethical Approval
The study was approved by the Regional Committee for Medical
and Health Research Ethics, and was conducted in accordance
with the Declaration of Helsinki. Written informed consent was
obtained from the children’s parents/legal representatives.
Magnetic Resonance Imaging (MRI)
Brain MRI scans were acquired using a 3T GE Signa HDxt MR
scanner (GE, Milwaukee, USA) equipped with an 8-channel head
coil. The followingMR protocol was used for acquisition of brain
metabolites:
1. PRESS sequence with TE = 35 ms and TR = 1500 ms, 128
averages giving a total acquisition time (TA) of 3:48 min.
2. MEGA-PRESS with TE = 68 ms and TR = 1500 ms, 128
averages each for edited and unedited parts giving TA =
7 min. The somewhat low number of averages was necessary
to minimize scan time with a difficult subject demographic.
GABA-editing was achieved with 16 ms 180◦ Gaussian
editing pulses applied at 1.9 ppm and 7.5 ppm with alternating
acquisition, giving the ‘‘edit-on’’ and ‘‘edit-off’’ spectra with
the GABA spectrum obtained by taking the difference between
the two acquisitions. Water reference lines were acquired
as a part of the acquisition both for PRESS and MEGA-
PRESS.
The MR scanning protocol also included a 3D T1 weighted
anatomical scan (number of slices = 192, slice thickness =
1.0 mm, repetition time (TR) = 7.8 ms, echo time (TE) =
2.95 ms, field of view = 260 × 260 mm2 flip angle = 14◦,
matrix = 256 × 256) for anatomical imaging and positioning of
the MRS voxel. The T1-images from the SPGR sequence were
reformatted from sagittal to oblique axial slice direction with
slices positioned parallel to the line connecting the lowest edge
of the splenium and the rostrum sections of the corpus callosum.
The ACC voxel was then positioned on the left side near the
midline of the brain between the genu and middle section of
the corpus callosum with the lower voxel edge tangential with
the upper border of corpus callosum, to avoid CSF, bone and fat
contamination.
MRS Data Analysis
Water-scaled metabolite concentrations from the PRESS and
the MEGA-PRESS data were analyzed with the LCModel
analysis software version 6.3-1H (Provencher, 1993). A simulated
MEGA-PRESS basis set and constrained baseline were used
in the fit. For valid PRESS results the standard deviation was
required to be %SD < 20% (Cramér-Rao lower bounds/CRLB)
and %SD < 20% for the GABA values in the MEGA-PRESS data
(Tables 1, 2).
The curve fitting of the GABA peak at 3.02 ppm was
visually inspected in each individual. Additional validation
was performed using an in-house quality-assurance script
implemented in Python.1 This script validates individual spectra
against a typical (group average) spectrum for the region and
identifies any aberrations in shape of the spectra or features
in the residuals—as would result from artifacts or poor fitting.
It additionally checks quantitative metrics such as linewidth,
signal-to-noise, and CRLB across the fit. This process is
intended to guide and to complement regular visual inspection
(Figure 2).
Statistics
Demographic data, ASSQ, intellectual ability (WASI) and MRS
data were analyzed using SPSS (version 12.01) (IBM Corp.
USA) statistical analysis software package. MRS measurements
were non-normally distributed, even after log transformation,
and results were thus analyzed using the non-parametric Mann
Whitney U-test and Skipped Pearson and Spearman correlation
(Pernet et al., 2013) with the level of significance being p ≤ 0.05.
The GABA+/Cr ratio was normally distributed and the Students
t-test was therefore applied.
Quantifying Tissue Composition
GABA tissue concentration has been demonstrated to differ
between gray matter (GM) and white matter (WM; Petroff
et al., 1988). The segmentation of GM, WM and CSF within
the MRS voxel was carried out on the 3D-SPGR images.
Segmentation was performed using in-house scripts based on
1https://www.python.org
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TABLE 1 | SNR (signal to noise ratio) and linewidth expressed as FWHM
(Full width at half maximum) in ppm.
MEGA-PRESS ASD (n = 14) TD (n = 21) P-value
SNR 20.7 ± 4.1/20.5 19.9 ± 2.6/20.0 0.41
FWHM 0.044 ± 0.014/0.038 0.038 ± 0.010/0.033 0.26
PRESS ASD (n = 14) TD (n = 24) P-value
SNR 26.6 ± 5.3/28.0 28.7 ± 2.6/29.0 0.39
FWHM 0.047 ± 0.015/0.046 0.044 ± 0.009/0.048 0.82
TABLE 2 | % CRLB (Cramer-Rao Lower Bound) for selected metabolites.
MEGA-PRESS ASD (n = 14) TD (n = 21) P-value
GABA+ 0.07 ± 0.015/0.07 0.07 ± 0.011/0.06 0.70
PRESS ASD (n = 14) TD (n = 24) P-value
Cr 0.02 ± 0.006/0.02 0.02 ± 0.004/0.02 0.94
NAA 0.02 ± 0.005/0.02 0.02 ± 0.003/0.02 0.25
MI 0.04 ± 0.007/0.03 0.03 ± 0.006/0.03 0.75
Cho 0.02 ± 0.004/0.02 0.02 ± 0.002/0.02 0.39
Glx 0.04 ± 0.008/0.04 0.04 ± 0.006/0.04 0.99
SPM’s unified segmentation and normalization functionality.2
The same software was also used to calculate total GM and WM
volume and total brain volume.
Results
Medication
Five of the 14 boys in the ASD group used
psychotropic medication; one was medicated with
lamotrigine (antiepilepticum), two with metylphenidate
(ADHD medication), one with aripriprazol (antipsychotic
medication) and one with metylphenidate and levetiracetam
(antiepilepticum). A further two used melatonin. None of the
participants in the TD group were on medication.
Autism Severity
All TD boys scored below the screening cut-off for ASD on the
ASSQ, and all the ASD boys scored higher than all the TD boys
(mean ASSQ score 23.5 in the ASD group vs. 1.5 in the TD group,
p < 0.001).
WASI Two Subtest Format
The results for the WASI total score and scores for the two
subtests are shown in Table 3.
As can be seen in Table 1, the ASD group scored below the TD
group on all three WASI variables. The difference is significant
for the Vocabulary scores, and approaches significance for the
Matrix Reasoning scores (p = 0.07). However, the total score
including both subtests was not significantly different between




Below is a summary of findings for both the PRESS and
MEGA-PRESS sequences in the two groups. Table 4 there were
no statistically significant differences between the two groups
(ASD/TD) in GABA+ and GABA+/Cr levels. For comparison
with previous studies, analyses were also performed with
GABA+/Glx and GABA+/NAA, but no statistically significant
differences between the two groups were found. See also scatter
plots for the distribution of GABA+ and GABA+/Cr in the two
groups (Figure 3).
There was a statistically significant negative correlation
between the ASSQ score and the GABA+/Cr concentration in
the ASD group, (Figure 4). The significant negative correlation
between GABA+ and ASSQ when using the Pearson correlation
coefficient did not hold when the skipped Pearson and skipped
Spearman test was applied.
The correlations did not survive correcting for multiple
comparisons due to the relative low number of participants.
Controlling for WASI did not change the strength or direction
of the correlation between ASSQ and GABA, but the statistical
significance was lost.
ASSQ is a questionnaire instrument applied to measure
autism severity with values above the cut off set at 17 indicating
ASD. The TD group all had ASSQ scores below 5. Still,
correlation analyses were performed between the ASSQ score and
GABA+ and the ratios and none of themwere statistic significant.
Tissue Segmentation
There were no group differences in total brain volumes and
segmented tissue volumes in the MRS voxel (Table 5). As no
systematic differences in tissue composition were observed, these
estimates were not considered further in the statistical analysis.
Discussion
In our correlation analyses we found significant negative
correlations in the ASD group between ASSQ score and
GABA+/Cr ratio, indicating that lower GABA+/Cr ratio is
associated with increasing autism severity.
This is the first paper, to our knowledge, that has examined
autism symptom severity and correlated this with metabolite
concentration measured from MRS using a MEGA-PRESS
sequence. However, our study supports the MEG-study by
Cornew et al. (2012) where they did find an association between
oscillatory anomalies, which suggest E/I imbalance, and autism
symptom severity. The participants in the Cornew study were 50
children, 27 with ASD and 23 age-matched controls, aged 6–15
years.
Our study did not reveal any group-level differences between
the ASD and the TD group regarding the concentration of
GABA+ and GABA+/Cr. These results do not fully support
all the results from the three previous studies (Harada et al.,
2011b; Gaetz et al., 2014; Rojas et al., 2014) that have applied
MRSMEGA-PRESS to compare brain GABA+ concentrations in
children with ASD.
Harada et al. (2011b) found significantly lower GABA+/NAA
and GABA+/Glu ratio in the ASD group, with a voxel placed in
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FIGURE 2 | Examples of a good and a poor quality MEGA-PRESS
spectrum. (A) The MEGA-PRESS spectrum shows a clearly visible GABA+
peak at 3.0 ppm. The difference between the data and the fitted curve, the
residual, is small indicating a good fit. (B) The MEGA-PRESS spectrum is noisy
with no clear GABA+ peak at 3.0 ppm. The residual is also large indicating a
poor fit.
TABLE 3 | WASI IQ scores.
ASD (n = 11) TD (n = 24) P-value
WASI, total score 97.6 ± 19.6/95.0 108.3 ± 14.3/107.0 0.11
Raw score Vocabulary 30.8 ± 15.4/34.0 40.4 ± 9.4/41.5 0.04
Raw score Matrix
Reasoning 19.7 ± 8.3/23.0 25.8 ± 9.3/26.5 0.07
Data are presented as mean ± standard deviation/median value.
the left frontal lobe, partly overlapping with our voxel placement
in the left ACC. Gaetz et al. (2014) found a significantly reduced
GABA+/Cr ratio in the ASD group in voxels placed in the
left motor and auditory cortex, while Rojas reported reduced
GABA+/Cr ratio in children with ASD and their unaffected
siblings compared to TD controls in a voxel placed in the left
auditory cortex (Rojas et al., 2014).
TABLE 4 | The summarized results for the quantization of relevant
metabolites from the MEGA-PRESS and PRESS sequences.
MEGA-PRESS ASD (n = 14) TD (n = 21) P-value
GABA+ 2.49 ± 0.40/2.53 2.66 ± 0.45/2.56 0.41
GABA+/Cr* 0.42 ± 0.066/0.42 0.44 ± 0.074/0.43 0.30
PRESS ASD (n = 14) TD (n = 24) P-value
Cr 6.01 ± 0.54/6.00 6.08 ± 0.39/6.05 0.71
NAA 8.61 ± 0.60/8.66 8.99 ± 0.73/9.08 0.10
MI 5.18 ± 0.87/5.08 4.98 ± 0.54/4.95 0.69
Cho 2.17 ± 0.21/2.16 2.19 ± 0.21/2.18 0.80
Glx 15.2 ± 1.58/15.00 15.49 ± 1.17/15.48 0.35
The concentrations obtained from the MEGA-PRESS experiment use water as an
internal concentration reference. *Cr from PRESS. Data are presented as mean ±
standard deviation/median. Values for metabolites are in Institutional Units.
An obvious difference between the three studies is that
the voxel placements in our study differed from the others.
The ACC region was chosen for voxel placement since
the area is implicated in the pathophysiology of ASD due
to its crucial role in social cognitive processes (Devinsky
et al., 1995; Bush et al., 2000; Amodio and Frith, 2006).
The ACC region is also known to be involved/affected in
patients with psychiatric disorder including schizophrenia,
obsessive–compulsive disorder, depression, post-traumatic stress
disorder and ASD (Benes, 1993; Rauch et al., 1994; Devinsky
et al., 1995; DeVito et al., 2007; Minzenberg et al., 2009).
Several recent studies implicate the ACC region in ASD,
and also connected it to imbalances in GABA/Glu. For
example, Naaijen et al. (2015) found aberrant fronto-striatal
glutamatergic levels, including the ACC in children with ASD.
Similarly, Cochran et al. (2015) found that glutamate-GABA
interaction and balance was disturbed in ASD subjects, and
that this correlated with social cognition measures. Finally,
Hall et al. (2015) used an auditory oddball task that requires
complex cognition, and measured both electrophysiology
responses and MRS glutamate levels from the ACC and
found a significant positive correlation between the two
indicating a specific connection between an index of glutamate
neurotransmitter function and frontal event-related potential.
Thus, the ACC region has been shown to be sensitive for subtle
changes in metabolite levels during social cognitive and rest
periods.
Both Harada et al. (2011b) and Gaetz et al. (2014) showed
that there might be regional differences as they found lower
concentration of GABA+ in ASD individuals in some areas of
the brain and with no group differences in other areas compared
to TD individuals. Further studies are needed to investigate the
role of voxel placements for GABA+ measurements.
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FIGURE 3 | Scatter plots showing the distribution of GABA+ ratios in the autism spectrum disorder (ASD) and typically developing (TD) groups.
(A) GABA+; (B) GABA+/Cr; (C) GABA+/NAA; and (D) GABA+/Glx.
Another possibility is that there are subgroups in the ASD
population where differences in GABA+ or the metabolites used
in the GABA+ ratio exist, whichmay explain the heterogeneity in
the ASD phenotype. All four studies on ASD children, referred
to in this manuscript, including our study, had small sample
sizes. The subjects in the Harada paper had a wide age range
(Harada et al., 2011b), and there was no information whether the
included subjects were boys or girls, while both boys and girls
were included in the Gaetz et al. (2014) and Rojas et al. (2014)
paper. In addition the Gaetz paper lacked sufficient information
about the recruitment of TD. As pointed out earlier, gender may
be a significant factor in predicting GABA+ levels (Harada et al.,
2011a; O’Gorman et al., 2011), however other studies have not
shown this difference (Puts and Edden, 2012). We need more
knowledge on how age and gender influences GABA+ levels and
we cannot rule out that such group differences contribute to the
previous results.
A strength in our study is that we only included boys, and
there were no age differences between the two study groups.
Moreover, both groups had total mean IQ scores within normal
range. Thus we think our results are representative for boys in
this age group. The discrepancy between the groups in IQ with
lower verbal IQ scores in the ASD group was expected, since it
reflects a clinical characteristic of children with ASD (Mayes and
Calhoun, 2003).
Controlling for WASI did not change the strength or
direction of the correlation between ASSQ and GABA+,
indicating that WASI was not a confounder in our analyses.
Thus the variation in performance on WASI (IQ) seems
secondary compared to a composite measure of ASD symptoms
(ASSQ) to describe the variation GABA+/Cr ratio in the ACC.
The lower GABA values were associated with more severe
ASD symptoms. More in depth neuropsychiatric tests were
not included in this study, therefore it is not possible to
evaluate performance of functions typically associated with
the ACC region such as executive control, theory of mind
etc. While there may be some association between regional
GABA+ content and neuropsychological performance, further
studies are needed to explore these possible confounding
factors.
Use of medication differed between the groups; 5 of 14
boys in the ASD group used psychotropic medication and an
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FIGURE 4 | Skipped Pearson and Spearman correlations with a 95% confidence interval (CI). The figures also include Bootstrapped Pearson and
Bootstrapped Spearmans plots. (A) ASSQ vs. GABA+/Cr; (B) ASSQ vs. GABA+.
additional two used melatonin, vs. no medications in the TD
group. GABA inhibition is a well-known target for therapeutic
anticonvulsant treatment, but neither of the two antiepileptic
drugs lamotrigine and levetiracetam have GABA enhancement
as their main effect (Olsen and Avoli, 1997). An MRS study
by Kuzniecky et al. (2002) showed a 25% increase in GABA
concentration on five healthy volunteers administered with long-
term dosing of lamotriginemeasured from a voxel in the occipital
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TABLE 5 | Results for the total brain volume ratios measured by tissue
segmentation, and results from tissue segmentation in the MRS voxel.
ASD TD P-value
Brain volume Gray 855 ± 72/865 882 ± 75/874 0.50
Brain volume White 405 ± 37/406 418 ± 42/422 0.38
Brain volume total 1261 ± 99/1277 1300 ± 112/1301 0.46
Voxel CSF 5.5 ± 4.7/4.3 3.4 ± 2.6/2.5 0.20
Voxel Gray 44.7 ± 5.6/45.2 45.2 ± 5.2/43.9 0.89
Voxel White 48.7 ± 10.3/53.0 51.3 ± 7.2/53.4 0.39
Data are presented as mean ± standard deviation/median. All volumes are in ml.
lobe. The exact mechanism of levetiracetam in treating epilepsy
is unknown, and in vivo studies of levetiracetam on whole mice
brain preparation haven not detected any differences on the
overall GABA and glutamate concentration (Sills et al., 1997).
All analyses were performed both with and without the two
boys using antiepileptic drug and it had no significant effect on
the results for the group level analyses.
Methylphenidate has a dopaminergic effect similar to
amphetamine and cocaine by blocking the dopamine and
noradrenaline transporters in pre-synapse, thus increasing the
availability of these neurotransmitters in the synaptic cleft.
GABA can modify the activity of dopaminergic neurons, and
psychostimulants (Pierce and Kalivas, 1997) may also influence
the activity of GABAergic neurons directly. One study on
female rats found that repeated treatment with methylphenidate
significantly increased the expression of GAD65 and GAD667
in the prefrontal cortex thus increasing vesicular GABA levels
(Freese et al., 2012). There is limited research available on
the effects of methylphenidate on GABA levels in humans;
therefore a possible impact on GABA levels cannot be
excluded.
An 18F-Fluoroflumazenil PET study on 17 patients with
schizophrenia found that aripiprazole administration resulted in
increased GABA transmission in the prefrontal cortex (Lee et al.,
2013).
Melatonin activates the benzodiazepine-GABAA receptor
complex with consequent enhancement of GABAergic activity
(Niles, 2006).
A common denominator of the four types of psychotropic
medication and melatonin is that they may all increase GABA+
levels, and they may thereby potentially mask an underlying
group difference in GABA+ level between the ASD and the
TD group. When comparing with the three other MEGA-
PRESS studies on children with ASD, we found no information
regarding epilepsy or usage of psychotropic medication in the
Harada et al. (2011b) paper. Gaetz et al. (2014) and Rojas
et al. (2014) excluded children with epilepsy from the ASD
group. In the Rojas et al. (2014) study five ASD children
used psychotropic medication, four SSRI and one an atypical
antipsychotic drug. In the Gaetz et al. (2014) study four
ASD children used psychotropic medication, two a SSRI,
one a ‘‘medication to treat mood disorder’’ and one atypical
antipsychotics. Regarding the effect of medication on GABA+/Cr
ratio, Rojas et al. (2008), Gaetz et al. (2014) and our own study are
comparable.
Most of the children in the Harada et al. (2011b) study were
sedated with triclofos sodium, a GABA agonist, which might
complicate the interpretation of their results. Reduced Glu and
increased GABA have been observed bilaterally in all cortical
regions examined following sedation with propofol (Zhang et al.,
2009), which is another GABA agonist. It may be that an effect of
sedation has influenced the MRS measurements and contributed
to their results.
Beyond any real underlying physiological variations, our
GABA+ measurements may also be affected by the different
MRI acquisition parameters used—in particular, the number of
averages. We chose to average over 128 pairs in order to keep
the scan time down and thereby minimize any errors due to head
movement. Lying completely still in the scanner is challenging
for children, and even more so for children with ASD. Both the
Harada et al. (2011b) and the Gaetz et al. (2014) paper used 128
averaged pairs in their MR protocols, while in the paper by Rojas
they averaged 256 pairs (Rojas et al., 2014), giving twice as many
spectral acquisitions and correspondingly improved signal-to-
noise, but also increasing the scan time significantly (to about
20 min with their TR of 2500 ms). A recent study from our group
(Craven abstract ISMRM 2014) suggests that an average of 256
pairs at TR = 1500 ms is more optimal for measuring GABA+
using MEGA-PRESS.
Applying the MEGA-PRESS GABA-editing MRS sequence
for measurement of GABA+ in the human brain has become
increasingly of interest during the last couple of years,
especially when evaluating neurochemical underpinnings of
psychiatric disorders. Even so, the most stable denominator for
normalized GABA+ measures, like basic sequence parameters
and specific method of spectral quantification, still remains
an active area of investigation. Thus, it is a possibility that
there exists a difference in GABA+ levels between groups,
but that we were not able to measure it. MR parameters,
like number of averages, and voxel placement are probably
more a factor than the MEGA-PRESS method itself, and with
further optimization a more subtle difference may become
apparent.
As mentioned in the introduction, ASD patients represent a
very heterogeneous group, probably reflecting variability within
the autism spectrum with different neurobiological substrates.
It is hardly likely that we will find one causal model for ASD.
Using different methods, e.g., questionnaires and standardized
interviews, to subgroup the ASD population and understand the
mechanisms involved may prove vital in future ASD studies,
including MRS studies.
Conclusion
We found a negative correlation between autism severity, as
measured by the ASSQ and GABA+/Cr in the ASD group, but
no GABA+ or GABA+/Cr level differences between ASD and TD
groups. The intricate balance between GABA and glutamate in
the brain in ASD is not completely understood. Recent evidence
even supports a deviant function of the GABA neurotransmitter
in children with ASDwith an excitatory rather than an inhibitory
effect indicating that absolute levels of GABA and glutamate may
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not reflect the E/I imbalance in the same way in ASD as in other
patient groups (Tyzio et al., 2014).
The present study clearly shows that autism severity must
be taken into account to elucidate the E/I hypothesis in autism.
Future studies with larger cohorts of ASD subjects in different
ages, severity and gender, and in different brain regions are
required to reveal the levels of GABA and glutamate and the
importance of the balance between them in relation to ASD
symptoms.
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Reproducibility of GABA Measurements
With MR Spectroscopy
Maiken K. Brix, MD,1,2* Lars Ersland, PhD,3,4 Kenneth Hugdahl, PhD,1,4,5,6
Gerard E. Dwyer, MS,5 Renate Gr€uner, PhD,1,4,7 Ralph Noeske, PhD,8
Mona K. Beyer, MD, PhD,9,10 and Alexander R. Craven, MS4,5
Purpose: The reproducibility of the MEGA-PRESS (MEshcher-GArwood Point RESolved Spectroscopy) MR spectroscopy
sequence for the measurement of gamma- aminobutyric acid (GABA) is addressed, focusing on optimizing the number
of repetitions at two voxel locations in the human brain and associated possibilities in analysis tools.
Materials and Methods: Two 20-min MEGA-PRESS acquisitions were run (echo time568 ms, repetition time5 1800
ms, repetitions5 328): one from a 21mL volume in the anterior cingulate cortex (ACC) and one from a 22mL volume in
the left Broca’s area in 21 healthy male volunteers (age 32 years6 6[SD]). Subjects were scanned twice with identical
protocols, 1 week apart. Data were acquired on a 3 Tesla GE Discovery 750 scanner using a 32-channel head coil. Spec-
troscopy data were partitioned into shorter epochs, numerically equivalent to scans of progressively increasing duration,
and compared both within and between sessions. Three different analysis schemes were applied: (1) Vendor prototype
preprocessor, with quantification by LCModel. (2) Pure Gannet pipeline. (3) Preprocessing with Gannet, and quantifica-
tion with LCModel. The coefficient of variation (CV) were calculated as a measure of reproducibility.
Results: Increasing the number of repetitions showed improvements for within- and between-session reproducibility up to
around 218 repetitions. (CV ranging from 4 to 14%). Gannet combined with LCModel approach proved the best method.
(CV5 4–5%). Measurements from the ACC area had higher CVs than the Broca area. (CV56–14% versus 4–7%).
Conclusion: Measurement in the Broca area yields better reproducibility than the ACC. With appropriate acquisition
times and preprocessing tools, measurements from the ACC area are also reliable.
Level of Evidence: 1.
J. MAGN. RESON. IMAGING 2017;00:000–000.
Gamma-aminobutyric acid (GABA) is the main inhibi-tory neurotransmitter in the brain and is present in
more than 30–40% of all synapses; only glutamate, the main
excitatory neurotransmitter, is more widely distributed.1 There
are few, if any, areas in the brain that are not affected by the
action of glutamate and GABA,1 and the widespread presence
and usage of these transmitters suggests that they are critically
involved in all major functions of the central nervous system
(CNS), as well as in various diseases and disorders of the CNS.2
MR spectroscopy (MRS) is a noninvasive method used
to measure the concentration of brain metabolites in health
and disease.3 By selectively exciting a volume of interest, a
voxel, in a specific brain region, metabolite concentrations
can be estimated by measuring characteristic resonances of
the various metabolites, at frequencies differing slightly from
that of water.
The concentration of GABA in the brain is relatively
low, ranging from 0.5 to 1.4 mmol/cm3 in healthy adults
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and is heterogeneously distributed throughout the brain.4
GABA is difficult to measure using standard MRS sequences
due to the spectral overlap with other metabolites with
higher concentration. One solution is to apply special spec-
tral editing techniques, such as the MEGA-PRESS
(MEshcher-GArwood Point RESolved Spectroscopy)
sequence.5
In the MEGA-PRESS sequence, a pair of frequency
selective inversion pulses are applied within a standard
PRESS sequence, allowing discrimination between overlap-
ping coupled and uncoupled spins. For GABA-editing, the
editing pulses are applied to the C-3 protons of GABA at
1.9 parts per million (ppm). Due to the spin–spin coupling,
the C-4 protons of GABA at 3.02 ppm are affected while
other metabolite peaks like the strong creatinine (Cr) peak
remains unaffected. Subtracting the spectrum from a second
acquisition with an editing pulse applied symmetric to the
water signal, at 7.5 ppm, will give a difference spectrum
without the strong singlet signal from Cr, allowing quantifi-
cation of the GABA peak at 3.02 ppm.
Conventional GABA editing sequences face challenges
due to co-editing of a signal arising from macromolecules at
3.0 ppm (J-coupled with a resonance at 1.7 ppm), which
superimposes on the GABA doublet and may contribute to
as much as 60% of the quantified value of GABA.6 Various
schemes have been proposed to minimize this factor, e.g,6–8
however, many of these suffer limitations, and none as yet
has been broadly adopted. For present purposes, we retain
the conventional sequence (with no additional macromole-
cule suppression) and denote our concentrations GABA1,
i.e., GABA plus an additional macromolecule contribution.
Both short-term9–11 and long-term12 between-session
and within-session13,14 variability studies indicates that indi-
vidual GABA levels are generally fairly stable in healthy sub-
jects, but also that the reproducibility of estimates varies in
different brain regions. In addition, studies e.g.,15 have
shown that the reproducibility of estimates from a given
dataset differ between software packages. Optimal parame-
ters for reliable GABA estimation with the MEGA-PRESS
sequence and subsequent processing of data is therefore,
important for reliable GABA measurements.
In an attempt to isolate any processing-specific issues
affecting reproducibility of the final quantification, different
combinations of preprocessor implementation and quantifi-
cation methods were investigated. Preprocessing was per-
formed with a vendor prototype pipeline,16 and using the
preprocessor component of the freely-available Gannet soft-
ware17. Preprocessed data were then fitted and quantified
using the ubiquitous LCModel18 and the standard fitting
component from Gannet 17.
Both preprocessors implemented coil combination,
zero-filling and line broadening before phase adjustment
and alignment of frames in the frequency domain. In
general, line broadening before modeling in LCModel
(http://s-provencher.com/pub/LCModel/manual/manual.
pdf ) is discouraged, and there could be at least two reasons
for this. The first is that it would broaden the peaks and
make it more difficult to separate nearby metabolites based
on fine details; for GABA1 this is a nonissue because only
one broad multiplet is being modeling. The other reason is
that it invalidates the signal-to-noise ratio (SNR) and the
CRLB estimates (line broadening will reduce noise). As a
result of this, these estimates are not reported in this manu-
script. The argument for retaining it is that it mitigates
some subtraction/phasing artifacts.
The Gannet preprocessor additionally performs outlier
rejection, to exclude frames exhibiting excessive frequency
shift (possibly indicative of subject motion or other transient
signal quality issues).
While LCModel attempts to model a broad section of
the acquired spectrum as a linear combination of basis sets,
The GannetFit component uses a comparatively simple non-
linear least squares approach to model the water signal and
the GABA peak at 3 ppm.
These current analyses enable us to measure the vari-
ability in GABA and use these estimates to calculate
required sample size in future GABA MRS experiments
involving correlations between GABA levels and behavior.
The time-windowing technique also allows us to do the
same required sample size calculations at different scan
lengths.
The purpose of this study addresses ongoing questions
of between- and within-session reproducibility of the
MEGA-PRESS sequence, focusing on optimizing the scan




Twenty-one healthy male volunteers (age 326 6[SD] years) were
recruited in accordance with approval by the local data protection
office and after obtaining written informed consent. Participants
were instructed to abstain from caffeine, alcohol, and nicotine,
exercise, and sex for the 12 h before each MR examination due to
possible influences on GABA levels.
MRI Acquisition
In vivo MEGA-PRESS data were acquired on a 3 Tesla (T) GE
Discover 750 scanner system (Milwaukee, WI) with the 32-
channel GE head coil, using echo time (TE)5 68 ms and repeti-
tion time (TR)5 1800 ms for 328 paired repetitions (20min),
acquiring 4096 datapoints at 5 kHz spectral width. The data were
acquired with eight-way phase cycling; averaging across the frame
was not performed at the time of acquisition (noadd option5 1).
A 16-ms sinc weighted Gaussian editing pulse was applied at
1.9 ppm (ON) and 7.46 ppm (OFF) in interleaved scans. One
acquisition was performed from a 21mL volume of interest in the
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mid anterior cingulate cortex (ACC) and the other from a 22mL
volume in the left Broca’s area. The ACC voxel was positioned in
the midline of the brain, angled in the sagittal plane aligned to the
foremost slope of the corpus callosum (CC). The rostral edges of
the voxel was aligned to the foremost border of the CC. The Broca
voxel was positioned in the left superior temporal lobe, centered
anterior to the anterior central gyrus. The voxel was angled in the
sagittal plan and aligned to the Sylvian fissure so that the bottom
four corners of the voxel were “resting” on the Sylvian fissure. See
Figure 1 for voxel placement. The order of acquiring the two areas
was randomized (balanced), to avoid any bias.
Rather than selecting regions known to be particularly suited
to the MEGA-PRESS acquisition, e.g., the occipital lobe,19 the
voxel placements were chosen for their relevance in basic neuro-
physiological and psychiatric research with critical involvement in
the default mode network, auditory processing and brain connec-
tivity in general.
The MR scanning protocol also included a three-
dimensional (3D) FSPGR T1 weighted anatomical scan (number
of slices5 188, slice thickness5 1.0mm, TR5 7.8 ms, TE5 2.95
ms, inversion time (TI)5 450 ms, field of view5 2563 256mm2
flip angle5 12 degrees, matrix5 2563 256) for anatomical imag-
ing and positioning of the MRS voxel.
All subjects were scanned twice with identical protocols, at
the same time of the day, 1 week apart. The subjects were
instructed to lie completely still during the acquisitions, although
no additional restraints were used; this mimics a standard MR-
session.
MRS Data Analysis
THE TIME WINDOW APPROACH. Long acquisitions (20min)
from each of the two regions were subdivided to produce datasets
equivalent to various shorter scan lengths (between 82 and 328
repetitions of edit on and off ). The subdivision was performed
after phase adjustment, coil combination, and realignment, just
before averaging across frames for subtraction of edited and unedit-
ed spectra. For any given acquisition, the same 16 water reference
frames were used with all shorter subsets.
The time-windowing approach is illustrated in Figure 2. To
assess between-session reproducibility for acquisitions of N repeti-
tions, the first N repetitions from the session one acquisition for
the chosen region were quantified, and compared with the first N
repetitions from the session two data for the same region.
To assess within-session reproducibility for acquisitions of N
repetitions, contiguous segments of N repetitions (beginning at
defined, regular positions) were extracted from individual acquisi-
tions and quantified; different segments from the same acquisition
were compared, as previously, using the same water reference
FIGURE 1: Voxel placement.
FIGURE 2: Application of the windowing method for between- and within-session reproducibility. Block sizes are expressed internally as
rational fractions of the total scan length; eight such subdivitions are examined (ref Table 1). The figures show a representative subset of
comparisons. (i) Between-session reproducibility. For each location, in each subject, the first N582 repetitions in session one are com-
pared with the first 82 repetitions in session two (red); the first N5164 repetitions in session one are compared with the first 164 repeti-
tions in session two, and so forth for various lengths up to N5328 repetitions (blue). The same 16 water reference frames (purple) are
used for each length N. (ii) Within-session reproducibility. For each location, subject and session, the entire scan is subdivided into evenly
distributed regions of length N, for various values of N from 82 (shown in red) through to 246 (green). The figure shows four conveniently
aligned sections for clarity, it is not that way for every length.
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FIGURE 3: Processing pipeline. (i) Processing pipline, overview. Processing pipeline used for windowed spectroscopy data analysis; The
vendor prototype and Gannet preprocessing Mathlab based tools were modified to add a masking and selection function immediately
before averaging for MEGA-PRESS subtraction and quantification. The three different analyzing approaches are depicted in the figure.
(ii) Time windowing, details. Bitmasks describing the selected subsets for analysis are applied to the MEGA-PRESS data. The same water
reference (magenta) is used for all subsets. The selected frames are averaged, and the MEGA-PRESS difference spectra is generated by
subtracting average ON frames from average OFF frames. Last, the difference spectra is fitted and quantification is performed in either
LCModel or Gannet.
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frames. For this case, data from session one and session two of
each subject were pooled.
ANALYSIS TOOLS. Three different tools were used, to evaluate
different combinations of preprocessor and fitting algorithm and
isolate any processor-specific sources of variation, see Figure 3 for
details. The Gannet and LCModel quantification methods use very
different approaches to modeling, both of which have demonstrat-
ed good reliability for GABA data 15. Both preprocessor imple-
mentations, GannetLoad and the vendor prototype, written in
Matlab (https://se.mathworks.com/products/matlab/ - version
2014b), were amenable to local modifications to implement the
time-windowing necessary for the current analysis.
WATER SCALING AND TISSUE CORRECTION. Values reported
herein are water scaled and adjusted for tissue content. In the case
of Gannet, this was performed using the Harris implementation20;
correction factors for macromolecule content (in vivo only) and
editing efficiency were also incorporated. For the LCModel case, in
vivo data were analyzed using LCModel’s default water concentra-
tions value (WCONC)5 35880, while phantom data were ana-
lyzed with WCONC5 55556; in both cases, estimates were
subsequently scaled to take into account water and metabolite
relaxation times in the different tissue classes and to account for
partial volume effects, according to tissue content estimates.
Metabolite relaxation times for GABA were taken as T15 1310/
2770 ms (in vivo/phantom),21 T25 88/276 (in vivo/phantom).22
Tissue content was derived from tissue priors and voxel
masks, based on the individual, nominal voxel placement; both
implementations used SPM (http://www.fil.ion.ucl.ac.uk/spm/soft-
ware/spm8/) for segmentation, and a local script for mask genera-
tion. We note that such adjustments have limited impact on
reproducibility metrics in the present context: for within-subject,
within-session comparison the placement (hence, tissue content) is
identical; between sessions the placement is nominally the same,
although slight variations inevitably occur; the average variation in
estimated tissue content between sessions was 4%.
A multi-factor quality assurance step was performed on the
fitted data, incorporating standard signal quality metrics from the
preprocessed spectra (SNR and linewidth, full-width half maximum
(FWHM)) standard deviation (CRLB) of metabolite estimate for the
fitted spectrum, and comparison of the fit and residual spectra
against a group average spectrum for the region to identify aberra-
tions in shape of the spectra or features in the residuals indicative of
signal artifacts or improper fit. This process guided regular visual
inspection of the spectra. Finally, strong outliers (corresponding with
biologically impossible estimates) were rejected; in total, two acquisi-
tions from the ACC placements were rejected on quality grounds.
Statistical Methods
Coefficients of variation (CVs) analysis were performed with Excel
(Microsoft Office 2010), and effect size and power analyses where
acquired with G*Power 3.1. All significance levels were set to 0.05.23
In Vitro Validation
As a benchmark for performance under ideal conditions, in vitro
phantom studies were included. The phantom MEGA-PRESS
acquisitions were performed using the same sequence parameters as
for human subjects, with a voxel size 22mL.
The metabolite solution was based on the GE “braino”
MRS-HD-Sphere spectroscopy phantom used in Schirmer and
Auer,24 with the following metabolite concentrations: 10mM
NAA, 10mM Creatine, 3mM Choline, 7.5mM Myo-Inositol,
10mM Glutamate, 5mM Lactate, with the addition of GABA at a
concentration of 2.85mM.
Data were quantified using the same processing pipeline and
time-windowing approach as described for the in vivo experiment,
with the exception of tissue correction.
Results
MRS
WITHIN-SESSION REPRODUCIBILITY. In both brain
regions, increasing the number of repetitions showed nota-
ble improvements in within-session reproducibility up to
around 218 repetitions. (i.e., approximately 13min). Fur-
ther increases resulted in only modest gains. The Gannet
combined with LCModel approach proved to be the best
method in both regions. In addition, measurements from
the ACC region had higher CV than the Broca region in all
three analyses approaches.
With both Gannet and LCModel quantification (and
either preprocessor), GABA estimates from the phantom
proved very stable across a range of scan durations, with
reproducibility improving gradually with the number of
averages. CVs of less than 5% were seen for a medium to
high number of averages. See Figure 4 for details.
BETWEEN-SESSION REPRODUCIBILITY. Again, in both
brain regions, increasing the number of repetitions showed
notable improvements in between-session reproducibility up to
around 218 repetitions. (i.e., approximately 13min). Further
increases resulted in only modest gains, and actually decreased
reliability beyond 262 repetitions in the ACC region. The
Gannet combined with LCModel approach proved to be the
better method in both regions. In addition, measurements
from the ACC region had higher CVs than the Broca region in
all three analyses approaches. See Figure 5 for details.
GABA1QUANTIFICATION RESULTS. GABA1 quantifi-
cation results for Broca and ACC and pure GABA quantifica-
tion in the phantom for all three quantification approaches
are presented in Table 1, with representative spectra shown in
Figure 6. While good quality spectra could be obtained in
both regions, the ACC data were somewhat more prone to
artifacts. Phantom data shows a better-defined doublet
around 3 ppm, which is masked by line broadening and mac-
romolecule contamination in the in vivo cases.
ESTIMATING POWER AND REQUIRED SAMPLE SIZE.
When plotting the mean GABA1 and SDs at different
number of repetitions for the ACC and the Broca area, with
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a power of 0.80, total required sample sizes can be calculat-
ed for different effects sizes, see Figure 7 (GABA1values
are from the tissue corrected LCModel1Gannet analyses).
For group experiments, more than 12 participants per group
are required to detect an effect size of 15% or greater in the
Broca area with 246 and 328 number of repetitions or in
the ACC area with 246 number of repetitions. The number
increases to 15 in both areas at 164 number of repetitions and
21 at 82 number of repetitions. Of interest, the number of par-
ticipants required to achieve an effect size of 15% increases to
23 in the ACC area when the number of repetitions are 328.
Discussion
Results from the phantom study indicate that the GABA1
MEGA-PRESS measuring method is reliable under optimal
conditions. Given the current sequence parameter settings,
we show that optimal acquisition time for in vivo studies
with voxel size 21–22mL is around 13min (218 repeti-
tions), but can be shorter if measuring in the Broca area.
The SNR increases in proportion to voxel volume but only
by the square root of the scan time. Therefore, one would
expect that the optimal number of repetitions would depend
on the voxel size. Measurements from the Broca area are
more consistent than from the ACC region, still our study
shows that data acquired from the ACC area can be reliable
if the appropriate acquisition times and the most optimal
software is chosen for the analyses. Gannet combined with
LCModel gave the best results in our data-analyses, and had
the best within- and between-subject reproducibility.
Although quantification of phantom data with Gannet
was quite accurate, the %SD and between-session variability
were comparatively high. Visual inspection shows the spec-
tral peaks to be significantly better defined in the phantom
case than the in vivo case, with a visible doublet around
FIGURE 5: Between-scan reproducibility for three different software options. The figure shows CV at different number of averages for
the in vivo Broca and ACC area and the phantom acquisition.
FIGURE 4: Within-scan reproducibility for three different software options. The figure shows CV at different number of averages for the
in vivo Broca and ACC area and the phantom acquisition.
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3.0 ppm (in vivo, the doublet peaks tend to merge due to
added MM contamination and increased line width). Con-
sequently, the curve fitting in Gannet (being tuned to model
in vivo data optimally) is less well suited to the phantom
spectra; this may well account for the higher %SD in phan-
tom measurements. While performance gains could be
expected by adjusting the model to better fit the phantom
data, in this instance we retained the standard model for a
more direct comparison.
In line with our results, a previous study from our
group25 found that the optimal scan length was 256 repeti-
tions in a 27-mL voxel placed in the occipital lobe. Also,
the most recent studies measuring GABA1 with MEGA-
PRESS uses between 256 and 28826–28 repetitions.
We found the within-session in vivo variability of
GABA1 levels at 218 repetitions to be 2.5–6% for Broca
and 5–13% for ACC and the between-session in vivo vari-
ability of GABA1 levels at 218 repetitions to be 4–7% for
TABLE 1. Representative GABA1 Quantification Values From In Vivo and Phantom Measurements (in mmol/L)a
Approach 1 (vendor prototype1LCModel)
No. of repetitions Broca %SD ACC %SD Phantom %SD
2.85b
82 2.17 5.00 1.65 7.25 2.19 6.00
108 2.26 4.33 1.66 6.58 2.17 6.50
164 2.26 4.13 1.69 5.88 2.17 6.50
197 2.24 4.17 1.73 5.67 2.17 6.50
220 2.27 4.00 1.67 5.63 2.16 6.50
246 2.29 4.00 1.69 5.63 2.15 6.50
328 2.48 3.67 1.66 5.50 2.17 6.00
Approach 2 (Gannet)
No. of repetitions Broca %SD ACC %SD Phantom %SD
2.85b
82 1.88 8.53 1.95 11.05 2.84 8.71
108 1.88 8.19 2.01 9.55 2.81 8.84
164 1.86 7.01 1.83 9.68 2.80 8.93
197 1.85 6.92 1.81 8.09 2.76 9.16
220 1.83 6.36 1.80 8.05 2.76 9.03
246 1.84 6.09 1.76 7.33 2.77 9.04
328 1.85 5.69 1.77 6.64 2.78 9.05
Approach 3 (Gannet1LCModel)
No. of repetitions Broca %SD ACC %SD Phantom %SD
2.85b
82 2.26 3.88 1.98 4.44 2.25 5.00
108 2.27 3.67 1.97 4.33 2.21 5.00
164 2.27 3.50 2.01 4.13 2.20 5.00
197 2.27 3.50 2.00 4.25 2.22 5.00
220 2.30 3.50 2.00 3.88 2.20 5.00
246 2.27 3.50 2.01 3.75 2.21 5.00
328 2.28 3.50 1.98 3.75 2.21 5.00
aThe %SD is measured across the group and represents inter-subject variability.
b2.85 is the nominal GABA1 concentration in the phantom.
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Broca and 6–13% for ACC. This is in line with previous
studies at 3T where CVs within session were found to be
13–18%13 in the occipital lobe and between session for
ACC were CV5 21,10 sensorimotor area CV5 12,9 occipi-
tal CV5 4.3–12.9,12
Only one system autoprescan is performed in the
beginning of each 20 min scan, and only one set of unsup-
pressed water lines are acquired meaning that the reproduc-
ibility results for the within session are not quite
comparable to other studies where this is collected for each
scan. Whether this will improve the reproducibility com-
pared with performing prescan and acquiring water lines for
each individual scan for the within-session results will
depend on how the prescan and water lines will effect, e.g.,
center frequency calculation, frequency drift, or editing effi-
ciency. Bogner et al’s13 within-session reproducibility num-
bers from the occipital lobe were derived after repeated
acquisitions with additional prescans and additional water
reference lines. The CV from their study (13–18%) were
higher than in this current study from an area that usually
has better B0 homogeneity compared with, e.g., the ACC
area, which might be due to these scan differences and
could therefore account for the difference in results between
the two studies. This may give better reproducibility and,
hence, could account for the differences in results between
the two studies.
The ACC has earlier proven to be a more difficult
area for GABA1 measurements compared with, e.g., the
occipital lobe and the sensory motor cortex.19 However, the
ACC has traditionally been thought as a more interesting
area for neuropsychiatric research. Our data suggests that
the most reliable GABA1 measurements can be achieved in
the ACC area when using 220–260 repetitions, and analyz-
ing the data with Gannet preprocessing combined with
FIGURE 6: Example spectra. Example spectra from the phantom acquisition and the in vivo acquisitions from the Broca and ACC area.
Also included are spectralfits from LCModel and Gannet.
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LCmodel. Of interest, further increasing the scan length
beyond a certain time can actually decrease reliability; this is
particularly evident in the ACC placement, perhaps due to
artifacts associated with regions of cerebrospinal fluid in the
proximity to that placement. There are many possible fac-
tors contributing to the degraded performance on very long
scans; the most likely is the cumulative effects of subject
motion toward the end of the long scan. While both pre-
processing methods can correct for associated changes in the
peak frequency by simply re-aligning the spectra, either to a
particular reference peak or to achieve maximum correlation
between the spectra, the efficiency of the editing pulse is
also affected by frequency shifts.
While the editing pulse is applied at a constant fre-
quency throughout the scan, the frequency of the editing
target may drift relative to this pulse resulting in distinct
variations in the efficiency of editing for GABA and any
macromolecule contamination.29 Variations in editing effi-
ciency are difficult to correct for retrospectively; effective
handling of this issue (perhaps incorporating real-time fre-
quency adjustment) is an area of active research.30 In many
settings, gradient-induced frequency drifts will also be a sig-
nificant factor; sequences of high gradient duty cycle (such
as EPI) may cause heating of various components (in partic-
ular, passive shim elements); thermal drift in the center fre-
quency may be observed as they subsequently cool. This is
seen as a gradual, somewhat linear change in center
frequency throughout the course of an MRS acquisition.
The presence and severity of this artifact will very much
depend on the scanner hardware, and the sequences run
before MRS acquisition. In the present study, gradient-
induced frequency drift is not a significant factor: our par-
ticular hardware has demonstrated relatively low vulnerabili-
ty to this problem; no gradient-heavy sequences were run
immediately before MRS data acquisition; no symptomatic
linear drift was observed in the center frequency of the scans
during processing. SD of the observed water frequency was
below 0.5Hz, with a drift throughout the scan of less than
2Hz.
As written in the introduction, the concentration of
GABA in the brain ranges from 0.5 to 1.4 mmol/cm3 in
healthy adults. Our quantification results lie above this,
which most likely is due to the fact that we measure
GABA1MM, and the coediting MM contributes to
approximately 60%6,31 of the measured signal.
This study does have limitations. The results in the
current study probably only apply for the two areas exam-
ined and were obtained in young male healthy subjects only.
A strength is the prospective longitudinal study design.
Because all participants were males, any gender effects were
excluded.15 In addition, the participants abstained from caf-
feine, alcohol and nicotine, exercise and sex for the 12 h
before each MR examination, due to possible influencing
the GABA1 levels.32–34 To minimize any circadian effects
on measured GABA1 levels,35 all participants were scanned
on the exact same time of the day, 1 week apart.
In conclusion, reliable meaningful GABA measure-
ments can be achieved in both the ACC area and the Broca
area when using appropriate scan parameters and corre-
sponding experimental design.
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